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Abstract 
 
Aims/hypothesis: Glucosamine, generated during hyperglycaemia, 
causes insulin resistance in different cells. Here we sought to evaluate 
the possible role of ER stress in the induction of insulin-resistance by 
glucosamine in skeletal muscle cells. Methods: Real-time RT-PCR 
analysis, 2-deoxy-D-glucose uptake and western blot analysis were 
carried out in rat and human muscle cell lines. Results: Glucosamine 
treatment causes both in rat and human myotubes a significant 
increase in the expression of the ER stress markers BIP, XBP1 and 
ATF6. In addition, glucosamine impairs insulin-stimulated 2-
deoxyglucose uptake both in rat and human myotubes. Interestingly, 
pre-treatment of both rat and human myotubes with the chemical 
chaperones PBA or TUDCA, completely prevents the effect of 
glucosamine on both ER stress induction and insulin-induced glucose 
uptake. Glucosamine treatment reduces GLUT4 mRNA and protein 
levels and the mRNA levels of the main regulators of GLUT4 gene, 
MEF2A and PGC1α, both in rat and human myotubes. Again, PBA or 
TUDCA pre-treatment prevents glucosamine-induced inhibition of 
GLUT4, MEF2A and PGC1α. Finally, we show that overexpression of 
ATF6 is sufficient to inhibit the expression of Glut4, Mef2a and Pgc1 
and that ATF6 silencing with a specific siRNA is sufficient to completely 
prevent glucosamine-induced inhibition of Glut4, Mef2a and Pgc1in 
skeletal muscle cells. Conclusions/interpretation: In this work we 
show that glucosamine-induced ER stress causes insulin-resistance 
both in human and rat myotubes and impairs GLUT4 expression and 
insulin-induced glucose uptake via an ATF6-dependent decrease of the 
Glut4 regulators Mef2a and Pgc1 
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Background 
 
1. Glucose homeostasis 
Despite periods of feeding and fasting, plasma glucose remains in a 
narrow range between 4 and 7mM in normal individuals. This tight 
control is governed by the balance between glucose absorption from 
the intestine, the production by the liver and the uptake and metabolism 
by peripheral tissues (Saltiel and Kahn 2001). Carbohydrate 
metabolism is regulated by several hormones, and also by sympathetic 
and parasympathetic nervous system activity (Table 1). The increasing 
glucose concentration after feeding (80/150 mg/dl) determines an 
increase of insulin release from pancreatic beta cells and a decrease of 
glucagon release from pancreatic alpha cells (Kahn 1994). Insulin 
lowers blood glucose levels both by suppressing glycogenolysis and 
gluconeogenesis in the liver (thereby decreasing hepatic glucose 
output), and by stimulating glucose uptake into skeletal muscle and 
adipose tissue. These actions are opposed by the “counter-regulatory” 
hormones, which are secreted continuously but whose release is 
enhanced during physiological “stress” (Pickup 2005). Thus, the correct 
efficiency of pancreatic beta cells in insulin synthesis and secretion 
represents a fundamental role in glucose homeostasis maintenance.   
 
 Liver 
Gluconeogenesis 
Glycogenolisys HGO Peripheral 
Glucose 
uptake 
Insulin ↓ ↓↓ ↓↓ ↑↑ 
 
Glucagon ↑↑§ ↑↑ ↑↑ - 
 
Catecholamines ↑↑*§ ↑ ↑↑ ↓ 
 
Growth hormone ↑* - ↑ ↓ 
 
Cortisol ↑*§ - ↑ ↓ 
 
Table 1. Main hormones affecting carbohydrate metabolism 
HGO, hepatic glucose output. 
*Indirect enhancement of gluconeogenesis due to increased supply of glycerol and 
fatty acids by enhanced lipolysis 
§Increased gluconeogenesis by effects on hepatic enzymes and increased supply of 
glucogenic amino acids 
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2. Insulin 
Insulin is the most potent anabolic hormone known. Secreted by 
pancreatic beta cells in response to the increase in plasmatic glucose 
and amino acids levels after feeding, insulin promotes the synthesis and 
storage of carbohydrates, lipids and proteins, while inhibiting their 
degradation and release into the circulation. Insulin stimulates the 
uptake of glucose, amino acids and fatty acids into cells, and increases 
the expression and  the activity of enzymes that catalyse glycogen, lipid 
and protein synthesis, while inhibiting the activity or the expression of 
those that catalyse degradation. Insulin increases glucose uptake in 
muscle and fat, and it inhibits hepatic glucose production 
(glycogenolyisis and gluconeogenesis) in liver, thus serving as the 
primary regulator of blood glucose concentration. Insulin also stimulates 
cell growth and differentiation, and promotes the storage of substrates 
in fat, liver and muscle by stimulating lipogenesis, glycogen and protein 
synthesis, and inhibiting lipolysis, glycogenolysis and protein 
breakdown (Figure 1) (Saltiel and Kahn 2001). 
 
 
 
 
 
Figure 1 The regulation of metabolism by insulin. 
Insulin promotes the synthesis and the storage of carbohydrates, lipids and proteins. 
Indeed, insulin stimulates the uptake of glucose, amino acids and fatty acids into cells, 
and increases the expression or  the activity of enzymes that catalyse glycogen, lipid 
and protein synthesis, while inhibiting the activity or the expression of those that 
catalyse degradation. 
 
Insulin is an hormone of 51 amino acids and is synthesized as a 
precursor protein (preproinsulin) in the beta cells. Preproinsulin 
presents a signal sequence at the N-terminus that allows its entrance in 
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secretion vesicles. The cut of the signal sequence by proteolytic 
enzymes produces proinsulin. When the increase in plasmatic glucose 
concentrations stimulates insulin secretion, proinsulin is converted in 
the mature hormone by specific proteases that hydrolyse two peptide 
bonds and generate mature insulin (Taylor, et al. 1999). Insulin is a little 
protein formed by two polypeptide chains, termed respectively “A” of 21 
amino acids, and “B” of 30, linked by two interchain sulphide bond. 
Once beta cells are stimulated by glucose, insulin is released in blood 
circulation and is distributed to target tissues, where it can bind a 
specific receptor at high affinity, essential for insulin signalling 
transduction. 
 
3. Insulin signaling system 
Insulin action is mediated through the insulin receptor (IR), a 
transmembrane glycoprotein with intrinsic protein tyrosine kinase 
activity. The insulin receptor belongs to a subfamily of receptor tyrosine 
kinases that includes the insulin-like growth factor (IGF)-I receptor and 
the insulin receptor-related receptor (IRR). These receptors are 
tetrameric proteins consisting of two α- and two β-subunits that function 
as allosteric enzymes where the α-subunit inhibits the tyrosine kinase 
activity of the β-subunit. Insulin binding to the α-subunit leads to 
derepression of the kinase activity of the β-subunit followed by 
transphosphorylation of the β-subunits and conformational change of 
the α subunits that further increases kinase activity (Patti and Kahn 
1998). Several intracellular substrates of the insulin receptor kinases 
have been identified (Figure 2). Four of these belong to the family of 
insulin-receptor substrate (IRS) proteins (White, et al. 1998). Other 
substrates include Gab-1 and isoforms of Shc10 (Pessin and Saltiel 
2000). The phosphorylated tyrosines in these substrates act as ‘docking 
sites’ for proteins that contain SH2 (Src homology-2) domains. Many of 
these SH2 proteins are adaptor molecules, such as the p85 regulatory 
subunit of PI(3)K and Grb2, or CrkII, which activate small G proteins by 
binding to nucleotide exchange factors. Others are themselves 
enzymes, including the phosphotyrosine phosphatase SHP2 and the 
cytoplasmic tyrosine kinase Fyn. PI(3)K has a pivotal role in the 
metabolic and mitogenic actions of insulin (Shepherd, et al. 1995). It 
consists of a p110 catalytic subunit and a p85 regulatory subunit that 
possesses two SH2 domains that interact with tyrosinephosphorylated 
motifs in IRS proteins (Myers MG Jr, et al. 1992). PI(3)K catalyses the 
phosphorylation of phosphoinositides on the 3-position to produce 
phosphatidylinositol-3-phosphates, especially PtdIns(3,4,5)P3, which 
bind to the pleckstrin homology (PH) domains of a variety of signalling 
molecules thereby altering their activity, and subcellular localization 
(Lietzke, et al. 2000). Phosphotidylinositol-3-phosphates regulate three 
main classes of signalling molecules: the AGC family of 
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serine/threonine protein kinases, the Rho family of GTPases, and the 
TEC family of tyrosine kinases. PI(3)K also might be involved in 
regulation of phospholipase D, leading to hydrolysis of 
phosphatidylcholine and increases in phosphatidic acid and 
diacylglycerol. The best characterized of the AGC kinases is 
phosphoinositide-dependent kinase 1 (PDK1), one of the serine kinases 
that phosphorylates and activates the serine/threonine kinase Akt/PKB 
(Alessi, et al. 1997). Akt/PKB has a PH domain that also interacts 
directly with PtdIns(3,4,5)P3, promoting membrane targeting of the 
protein and catalytic activation. Akt/PKB has a pivotal role in the 
transmission of the insulin signal, by phosphorylating the enzyme GSK-
3, the forkhead transcription factors and cAMP response element-
binding protein. Other AGC kinases that are downstream of PI(3)K 
signaling include the atypical PKCs, such as PKC-ζ. Akt/PKB and/or the 
atypical PKCs are required for insulin stimulated glucose transport 
(Standaert, et al. 1997). 
As is the case for other growth factors, insulin stimulates the 
mitogenactivaed protein (MAP) kinase extracellular signal regulated 
kinase (ERK) (Figure 2). This pathway involves the tyrosine 
phosphorylation of IRS proteins and/or Shc, which in turn interact with 
the adapter protein Grb2, recruiting the Son-of-sevenless (SOS) 
exchange protein to the plasma membrane for activation of Ras. The 
activation of Ras also requires stimulation of the tyrosine phosphatase 
SHP2, through its interaction with receptor substrates such as Gab-1 or 
IRS1/2. Once activated, Ras operates as a molecular switch, 
stimulating a serine kinase cascade through the stepwise activation of 
Raf, MEK and ERK. Activated ERK can translocate into the nucleus, 
where it catalyses the phosphorylation of transcription factors such as 
p62TCF, initiating a transcriptional programme that leads to cellular 
proliferation or differentiation (Boulton, et al. 1991). 
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Figure 2 Signal transduction in insulin action. 
The insulin receptor is a tyrosine kinase that undergoes autophosphorylation, and 
catalyses the phosphorylation of cellular proteins such as members of the IRS family, 
Shc and Cbl. Upon tyrosine phosphorylation, these proteins interact with signaling 
molecules through their SH2 domains, resulting in a diverse series of signaling 
pathways, including activation of PI(3)K and downstream PtdIns(3,4,5)P3 dependent 
protein kinases, Ras and the MAP kinase cascade. These pathways act in a 
concerted fashion to coordinate the regulation of vesicle trafficking, protein synthesis, 
enzyme activation and inactivation, and gene expression, which results in the 
regulation of glucose, lipid and protein metabolism. 
 
4. Skeletal muscle glucose uptake regulation: a role for GLUT4 
Insulin-stimulated glucose uptake by skeletal muscle plays an important 
role in the maintenance of whole-body glucose homeostasis. Glucose 
transporter 4 (GLUT4) is the main glucose transporter isoform 
expressed in skeletal muscle that mediates glucose uptake in response 
to hormones such as insulin, to stimuli such as exercise/contraction and 
hypoxia, and to pharmacological interventions that alter mitochondrial 
energy output. Under basal conditions, GLUT4 is predominantly 
sequestered in several intracellular compartments. Both insulin and 
muscle contraction cause a net gain of GLUT4 at the plasma 
membrane to increase glucose uptake, but they utilize distinct signalling 
molecules and mobilize GLUT4 from different intracellular pools. It is 
well accepted that activation of the insulin receptor substrates 
(IRS)/phosphatidylinositol 3-kinase (PI3K) axis is indispensable to 
insulin-stimulated GLUT4 translocation and glucose uptake (Figure 3). 
Similarly, it is well documented that 2 serine/threonine kinases (Akt and 
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the atypical protein kinase C [aPKC] zeta/lambda downstream of PI3K) 
participate in mediating insulin’s metabolic actions in skeletal muscle 
and fat (Klip  2009).  
The GLUT4 gene is subject to complex tissue-specific and metabolic 
regulation, with a profound impact on insulin mediated glucose disposal. 
The human GLUT4 promoter is regulated through the cooperative 
function of two distinct regulatory elements, domain 1 and the myocyte 
enhancer factor 2 (MEF2) domain. The MEF2 domain binds 
transcription factors MEF2A and MEF2D in vivo; domain 1 binds the 
transcription factor GEF (GLUT4 enhancer factor). MEF2A and GEF 
coimmunoprecipiteted and function together to activate GLUT4 
transcription. No much is known about GEF (Knight et al. 2003). By 
contrast, it is well established that MEF2 plays a role in the 
transcriptional regulation of different cellular functions in skeletal and 
cardiac muscle, neurons, and T cells. To respond to diverse 
developmental and physiological cues, MEF2 is structurally organized 
to receive and respond to multiple signals from several intracellular 
signaling pathways. Consistent with its role as a signal sensor, putative 
phosphoacceptor motifs in the carboxyl terminal MEF2 transactivation 
domain may prove to further modulate MEF2 stability and function in 
response to extracellular cues. By contrast, the ubiquitous 
phosphorylation of Ser-255 by endogenous kinases is detected in 
several cell types (C2C12, COS, and HeLa) and is coupled with its role 
in the degradation of MEF2. This phosphorylation points tantalizingly 
toward a role for glycogen synthase kinase 3. This ubiquitous kinase is 
now known to be involved in numerous cellular signaling functions and 
to phosphorylate several proteins, which are subsequently targeted for 
degradation (Cox et al.  2003). Finally, GLUT4 trascription can be 
modulated by other proteins, such as peroxisome proliferators-activated 
receptor- coactivator 1 (PGC-1) (Al-Khalili et al. 2005). Indeed, MEF2D 
binds PGC1 recruiting this transcriptional coactivators to MEF2A.  
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Figure 3 Insulin-induced glucose uptake in muscle.  Insulin regulates glucose 
uptake into muscle cells by recruiting membrane vesicles containing the GLUT4 
glucose transporters from the interior of cells to the cell surface, where it allows 
glucose to enter cells by facultative diffusion.  Once in the cytoplasm, the glucose is 
phosphorylated and thereby trapped inside cells. The effect of insulin on GLUT4 
distribution is reversible.  Within an hour of insulin removal, GLUT4 is removed from 
the membrane and restored intracellular in vesicles ready to be re-recruited to the 
surface by insulin.  Thus, glucose uptake by muscle cells is regulated by modulating 
the number of GLUT4 glucose transporters on the surface of cells.   
 
5. Diseases with altered glucose homeostasis 
Maturity-onset diabetes of the young (MODY), Persistent 
Hyperinsulinemic Hypoglycemia of Infancy (PHHI), mitochondrial 
diabetes, Type 1 (T1D) and Type 2 Diabetes (T2D) are a 
heterogeneous group of disorders characterized by high blood glucose 
levels and by insulin secretory abnormalities. In subjects with MODY, 
PHHI, or mitochondrial diabetes, the elevation in blood glucose levels is 
due to genetically determined defects in processes that are critical for 
the normal signaling pathways in the beta cell. The effects of these 
mutations on insulin secretion are so severe that diabetes develops in 
people with normal or relatively normal insulin sensitivity and without 
the contribution of environmental factors. In T1D, instead, insulin 
secretory abnormalities results from an absolute deficiency of insulin 
due to autoimmunological destruction of the insulin-producing 
pancreatic beta cell. Finally, in T2D, more moderate abnormalities of 
secretion are present that cause glucose intolerance only if insulin 
resistance is also present. The genetic basis of beta cell dysfunction in 
this form of diabetes is more complex, involving both multiple interacting 
genes and environmental factors, which determine whether diabetes 
will develop and at what age. Here no genetic abnormalities profoundly 
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affect beta-cell function, but rather the inability of the pancreatic beta 
cell to adapt to the reductions in insulin sensitivity that occur over a 
lifetime precipitates the onset of hyperglycaemia (Bell and Polonsky 
2001). 
 
5.1 MODY, PHHI, and mitochondrial diabetes 
MODY is a clinically heterogeneous group of disorders characterized by 
nonketotic diabetes mellitus, an autosomal dominant mode of 
inheritance, onset usually before 25 years of age and frequently in 
childhood or adolescence, and a primary defect in pancreatic beta cell 
function. MODY can result from mutations in any one of at least six 
different genes that encode the glycolytic enzyme glucokinase and five 
transcription factors: hepatocyte nuclear factor (HNF)-4α, HNF-1α, 
insulin promoter factor-1 (IPF-1), HNF-1β and neurogenic differentiation 
1/beta cell E-box transactivator 2 (NeuroD1/BETA2) (Table 2). All the 
mentionated genes are expressed in the pancreatic beta-cell and 
mutations lead to beta cell dysfunction and diabetes mellitus in the 
heterozygous state (Bell and Polonsky 2001). 
 
                          
MODY Gene involved 
MODY 1 HNF-4α 
MODY 2 GK 
MODY 3 HNF-1 α 
MODY 4 IPF-1 
MODY 5 NEURO D1/BETA 2 
              Table 2 MODY classification and genes 
 
GK is expressed at highest levels in the pancreatic beta cell and in the 
liver. It catalyses the transfer of phosphate groups from ATP to glucose 
to generate glucose-6-phosphate: the first rate-limiting step in glucose 
metabolism. GK functions as the glucose sensor in the beta cell and 
influences the ability to store glucose as glycogen in the liver. 
Heterozygous mutations leading to partial deficiency of GK are 
associated with MODY and homozygous mutations usually result in 
complete deficiency of this enzyme, leading to PHHI (Bell and Polonsky 
2001). The transcription factors HNF-1α, HNF-1β and HNF-4α are 
involved in the tissue-specific regulation of gene expression in the liver, 
pancreatic beta cells and other tissues. HNF-1α and HNF-1β are 
members of the homeodomain containing family of transcription factors 
and HNF-4α is an orphan nuclear receptor. They are part of a network 
of transcription factors that controls gene expression during embryonic 
development and also in adult tissues where they are co-expressed. In 
the pancreatic beta cell, they regulate the expression of genes 
important in the regulation of insulin secretion. Mutations in these genes 
produce defects in insulin secretory responses to a variety of factors, 
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particularly glucose, which are present before the onset of 
hyperglycaemia. In mice lacking the gene for HNF-1α, beta cell mass 
fails to increase despite the presence of hyperglycaemia, suggesting 
that this transcription factor may regulate beta cell mass (Bell and 
Polonsky 2001). 
IPF-1 is a homeodomain-containing transcription factor involved in 
pancreatic development, transcriptional regulation of a number of beta 
cell genes including insulin, glucokinase, islet amyloid polypeptide and 
GLUT2, and mediation of glucose-stimulated insulin gene transcription. 
Mutations in the heterozygous state are associated with MODY, 
whereas mouse and human homozygotes fail to develop a pancreas 
and suffer congenital diabetes mellitus. IPF-1 mutations have also been 
discovered in a small fraction of patients with typical adult-onset type 2 
diabetes. Subjects with heterozygous mutations in IPF-1 demonstrated 
reduced insulin secretory responses to glucose and glucagon-like 
peptide-1, consistent with a defect in the signalling pathways that 
regulate secretion in the beta cell and/or a defect in beta cell mass. The 
basic helix–loop–helix transcription factor NeuroD1/BETA2 is involved 
in the regulation of transcription of the insulin gene and is required for 
normal pancreatic islet development. Mutations in NeuroD1 are a rare 
cause of MODY and result in reduced serum insulin concentrations, 
either due to a signalling defect in the beta cell, or a reduction in beta 
cell mass, or both (Bell and Polonsky 2001). PHHI, also known as 
familial hyperinsulinism, pancreatic nesidioblastosis or hyperinsulinemic 
hypoglycemia, is a rare genetic disease, that can be inherited in a 
dominant or recessive way. It is mainly characterized by the presence 
of inappropriately high levels of insulin in parallel with low or very low 
glucose levels. This disease affects newborns and infants and it is as 
frequent as 1:50000 for unselected populations. Mutations in four 
different genes have been identified: the KATP channel genes SUR1 
and Kir6.2, glucokinase (GK), and glutamate dehydrogenase (GLUD1). 
Nevertheless, in as many as 60% of patients, the genetic basis of the 
condition has not been elucidated. The most common and most severe 
forms of PHHI arise from SUR1 (40 different mutations) and/or Kir6.2 
(three mutations) gene defects and alterations of beta cellular KATP 
channels are responsible for PHHI physiopathology. Using both 
recombinant expression systems and beta cells isolated from patients 
after surgery, investigators have shown these mutations to lead to 
impaired trafficking or assembly of KATP channels or to cause defects 
in the ADP dependent regulation of channel activity, and it results in 
depolarized beta cells with unregulated Ca2+ channel activity, that 
determines hypoglycaemia and impaired insulin secretion (Kane et al. 
1996; Straub et al. 2001). In addition to mutations in the nuclear 
genome, abnormal mitochondrial function resulting from mutations in 
the mitochondrial genome can lead to diabetes. The most common 
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diabetes-associated mutation is an A-to-G transition in the mito-
chondrial tRNALeu (UUR) gene at base pair 3,243. This mutation 
results in defects in insulin secretion including failure of glucose to 
prime the insulin secretory response and abnormal insulin secretory 
oscillation (Bell and Polonsky 2001). 
 
5.2 Type 1 diabetes 
T1D accounts for 10% of all diabetes cases. The disease can affect 
people of any age, but usually occurs in children or young adults. T1D 
is caused by an auto-immune reaction againist the insulin-producing 
cells. The reason why this occurs is not fully understood. T1D 
pathogenesis involves environmental triggers that may activate 
autoimmune mechanisms in genetically susceptible individuals. It is 
characterized by insulitis, an infiltration of the pancreatic islets by 
lynphocytes, macrophages and neutrophil granulocytes, resulting in 
auto-immune destruction of the beta cells since chronic exposure to 
proinflammatory cytokines such as IL-1, TNFα, and interferon γ is 
cytotoxic to beta cells. The clinical manifestation of T1D is typically late-
stage, when majority of beta cells (90%) have been destroyed and its 
onset is often sudden and dramatic. The lives of people with this form of 
diabetes are entirely dependent on injections of insulin every day for 
survival in order to prevent the development of ketoacidosis. (Diabetes 
Atlas 2006). 
 
5.3 Type 2 diabetes 
T2D is the most common type of diabetes and accounts for 90% of all 
forms of diabetes. T2D is most common in people older than 45 who 
are overweight. However, as a consequence of increased obesity 
among young people, it is becoming more common in children and 
young adults. T2D is a heterogeneous syndrome with many possible 
causes. This is due to the interaction of environmental factors with a 
genetic susceptibility to the disease (Table 3), and it is becoming more 
and more evident that the relative contribution of genes and 
environment can differ considerably, even among individual whose 
clinical phenotype is similar (Diabetes Atlas 2006).  
The maintenance of normal glucose homeostasis depends on a 
precisely balanced and dynamic interaction between tissue sensitivity to 
insulin and insulin secretion. Type 2 diabetes develops because of 
defects in both insulin secretion and action, both of these with a genetic 
as well as an acquired component. Thus, T2D is made up of different 
forms each of which is characterized by variable degrees of insulin 
resistance and beta cell dysfunction, and which together lead to 
hyperglycaemia. Insulin resistance, typically, is an early feature of T2D. 
It results from a genetically determined reduction in insulin sensitivity, 
compounded by exposure to the environmental factors, which further 
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impair insulin action. Major sites of insulin resistance include liver and 
the peripheral tissues, skeletal muscle and fat. In muscle and fat, insulin 
resistance is manifested by decreased glucose uptake; in muscle, it 
impaires glucose utilization by nonoxidative pathways as well as by a 
decrease in glucose oxidation; in the liver, insulin resistance leads to 
failure of insulin to suppress hepatic glucose production, which is 
followed by glycogen breakdown and particularly by gluconeogenesis 
(Pickup 2005) (Figure 4). 
 
 
 
 
Figure 4 Insulin resistance on tissue targets. 
The main sites of insulin resistance are liver and the peripheral tissue, skeletal muscle 
and fat. Insulin resistance is manifested by decreased glucose uptake in muscle and 
fat, and by failure of insulin to suppress hepatic glucose production in the liver. 
 
The beta cell dysfunction, the other key component of T2D 
pathophysiology, involves a relatively selective defect in the ability of 
glucose to stimulate insulin secretion by beta cells, a temporal 
irregularity in the pulse and oscillations of insulin secretion, and a loss 
of the tight coupling between pulses of insulin secretion and pulse in 
glucose. This defect accounts for the failure of beta cells to compensate 
for increasing insulin-resistance and for the ultimate development of 
overt hyperglycaemia.  
The disease often remains asymptomatic and undetected for years. 
People with T2D do not usually require injections of insulin, and they 
control their blood glucose levels by watching their diet, taking regular 
exercise, oral medication, and possibly insulin. But if T2 diabetic people 
are not diagnosed and treated, they can develop serious complications, 
which can result in early death. Indeed, as glycaemic control 
deteriorates over time, patients are at increased risk of microvascular 
complications (disease of the small blood vessels) including 
retinopathy, neuropathy and nephropathy, and macrovascular 
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complications (disease of the large blood vessels) including coronary 
heart disease, myocardial infarction and stroke. As a result, diabetes 
affects almost every element of the human body, (Figure 5).  
 
Figure 5 The major diabetic complications. 
Diabetic patients are at increased risk of microvascular complications (disease of the small 
blood vessels) including retinopathy, neuropathy and nephropathy, and macrovascular 
complications (disease of the large blood vessels) including coronary heart disease, myocardial 
infarction and stroke. 
 
Major risk factor 
Demographic factors 
- Race and ethnic background (native American, Polynesian islanders, African-
American) 
- Age ≥ 45 years 
Family history: first-degree relatives with type 2 diabetes 
Obesity: BMI ≥ 27 Kg/m2 with central fat distribution 
History of impaired fasting glucose or impaired glucose tolerance 
Hypertension (blood pressure ≥ 140/90 mmHg) 
HDL cholesterol level ≤ 0.90 mmol/l and/or a triglyceride level ≥2.8 mmol/l 
Other risk factors 
Malnutrition in the first year of life, and particularly in utero 
Lifestyle factors 
- Physical inactivity 
- High-fat, low-carbohydrate diet 
- Alcohol (heavy consumpition) 
- Smoking 
Table 3. Main risk factors for T2D 
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6. “Glucotoxicity ” and its role in the induction of insulin 
resistance. 
As said before, chronic hyperglycemia is a characteristic of the diabetic 
condition, while glucose toxicity is the main cause of diabetic 
complications, which are often observed only several years after the 
beginning of the illness (Reusch  2003) 
Glucose toxicity, in its narrow sense, can indicate a clinical condition 
where control of diabetes in particular is poor, since hyperglycemia itself 
reduces the insulin secretion capacity of pancreatic β-cells, and the 
resultant increase in insulin resistance leads to further hyperglycemia. 
This vicious circle finally leads to the total incapacity of β-cells to 
secrete insulin (LeRoith 2002; Dubois, Vacher 2007). Despite the 
recognized implications of glucotoxicity in generation of tissue damage 
in diabetes, still little is known about the possible impact of 
hyperglicemia on insulin resistance.  
It is well established that chronic hyperglycaemia per se promotes 
insulin resistance (Hager 1991; Davidson 1994) and a number of 
mechanisms have been proposed to explain hyperglycemia-induced 
insulin resistance; these include activation of oxidative stress (Evans  
2007), increased formation of advanced glycosylation end products 
(AGE) or their precursor methylglyoxal (Miele 2003; Van Obberghen 
2006) and increased flux trough the hexosamine pathway (Buse 2006) 
by chronically elevated glucose concentrations. However, the molecular 
mechanism(s) through which hyperglycaemia exacerbates insulin 
resistance in diabetes have only partially been elucidated. 
 
6.1 Glucotoxicity, oxidative stress and insulin-resistance 
Glucotoxicity participates in insulin resistance of insulin-sensitive 
tissues, which include liver, skeletal muscle, and adipose tissue and 
oxidative stress is strongly suspected to be involved in this process. 
(Eriksson 2007). Indeed, it is known that incubation of primary 
adipocyte cells with chronic high glucose concentration can induce 
oxidative stress (Lu 2001). Moreover, it was demonstrated that 
oxidative stress induces insulin resistance in the 3T3-L1 adipocyte cell 
line by inhibiting the translocation of Glut 4 to the plasma membrane 
(Rudich 1998). Finally, it was found that oxidative stress can induce 
insulin resistance in intact rat muscle (Dokken 2008). Through in vitro 
studies and in animal models of diabetes, it has been found that 
antioxidants, especially α-lipoic acid (LA), improve insulin sensitivity 
(Maddux 2001). Several clinical trials, even if small and of short 
duration, have also demonstrated that treatment with vitamin E, vitamin 
C, or glutathione improves insulin sensitivity in insulin-resistant 
individuals and/or patients with type 2 diabetes (Evans 2003).  
In vitro, ROS and oxidative stress lead to the activation of multiple 
serine kinase cascades (Kyriakis 1996). The insulin signaling pathway 
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offers a number of potential targets (substrates) of these activated 
kinases, including the insulin receptor (IR) and the family of IR substrate 
(IRS) proteins. For IRS-1 and -2, an increase in serine phosphorylation 
decreases the extent of tyrosine phosphorylation and is consistent with 
the attenuation of insulin action. In Chinese hamster ovary cells, stress 
activation of JNK/SAPK increased serine phosphorylation (at Ser307) 
and inhibited insulin-stimulated tyrosine phosphorylation of IRS-1. In L6 
muscle cells, H2O2-mediated inhibition of insulin-stimulated glucose 
transport was accompanied by activation of p38 MAPK by H2O2 (Blair 
1999). Insulin-stimulated glucose transport could be restored by LA or 
by a specific inhibitor of p38 MAPK (Blair  1999).  
Activation of IKK-β, a serine kinase that regulates the NF-κB pathway, 
also inhibits insulin action (Yuan 2001). Salicylates lower blood glucose 
(Yuan 2001), augment glucose-induced insulin secretion in normal 
subjects, and restore insulin secretion in patients with type 2 diabetes. 
In addition, salicylates inhibit IKK-β activity and restore insulin 
sensitivity, both in vitro and in vivo. Treatment with aspirin or salicylates 
alters the phosphorylation patterns of IRS proteins, resulting in 
decreased serine phosphorylation, increased tyrosine phosphorylation, 
and improved insulin action (Yuan 2001). Further support for the 
importance of IKK-β in insulin resistance is provided by results of recent 
gene knockout experiments in mice. IKK-β (+/−) heterozygotes were 
more insulin sensitive compared with their normal (+/+) littermates 
(Yuan 2001). Treatment of nine type 2 diabetic patients for 2 weeks with 
high dosages of aspirin (7g/day) resulted in reduced hepatic glucose 
production and fasting hyperglycemia and increased insulin sensitivity. 
Although these latter data are preliminary and require confirmation in an 
expanded study, they are consistent with a role for activation of IKK-β in 
the pathogenesis of insulin resistance. Furthermore, they suggest that 
inhibition of IKK-β might be an attractive pharmacological approach to 
increasing insulin sensitivity.  
 
6.2 Glucotoxicity , increased intr acellular formation of advanced  
glycation end-products, methylglyoxal and insulin resistance. 
An additional deleterious effect of chronic hyperglycemia is the 
increased production of advanced glycation end products (AGEs). 
AGEs can arise from intracellular auto-oxidation of glucose to glyoxal 
(Wells-Knecht 1995), decomposition of the Amadori product (glucose-
derived 1-amino- 1 deoxyfructose lysine adducts) to 3-deoxyglucosone 
(perhaps accelerated by an amadoriase), and fragmentation of 
glyceraldehyde- 3-phosphate and dihydroxyacetone phosphate to 
methylglyoxal (Thornalley 1990). These reactive intracellular 
dicarbonyls, glyoxal, methylglyoxal and 3-deoxyglucosone, react with 
amino groups of intracellular and extracellular proteins to form AGEs. 
Methylglyoxal and glyoxal are detoxified by the glyoxalase system 
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(Thornalley 1990). All three AGE precursors are also substrates for 
other reductases (Suzuki 1998). The modifications of proteins that lead 
to their glycation induce alterations in their biological properties as 
compared with their non-glycated counterparts. Production of 
intracellular AGE precursors damages target cells by three general 
mechanisms. First, intracellular proteins modified by AGEs have altered 
function. Second, extracellular matrix components modified by AGE 
precursors interact abnormally with other matrix components and with 
the receptors for matrix proteins (integrins) on cells. Third, plasma 
proteins modified by AGE precursors bind to AGE receptors on 
endothelial cells, mesangial cells and macrophages, inducing receptor-
mediated production of reactive oxygen species. This AGE receptor 
ligation activates the pleiotropic transcription factor NF-kB, causing 
pathological changes in gene expression (Hattori  2001). 
Although glycated albumin has initially thought to be involved only in the 
generation of diabetes complications (Bronwlee 2005), there are 
accumulating evidences that strongly support the idea that glucose-
derived products also affect insulin signaling. As said before, glycated 
albumin and AGEs exert their effects through specific cellular receptors 
found in different cell types and through the activation of several 
signaling pathways (Schmidt 2000; Wu 2001). Recently, Naitoh et al. 
(Naitoh 2001) demonstrated that, in human monocytic cells, glycated 
albumin induces the release of TNF-α, a factor involved in insulin 
resistance (Peraldi  1998).  
Moreover in L6 skeletal muscle cells, exposure to human glycated 
albumin selectively inhibits the PI3K/PKB branch of the insulin signaling 
cascade, while leaving the Ras-ERK pathway and mitogenic action of 
the hormone unaltered. Mechanistically, HGA-mediated PI3K/PKB 
inhibition is dependent on a PKCα-mediated serine/threonine 
phosphorylation of IRS-1/2 proteins that leads to a strong decrease in 
insulin-regulated metabolic responses, such as glucose uptake and 
glycogen synthesis. Interestingly, activation of PKCα by chronic HGA 
treatment appears to be independent of ROS production. Thus, by 
deregulating intracellular insulin signaling, human glycated albumin 
exacerbates the insulin-resistant state (Miele 2003).  
In addition it has been demonstrated that, in L6 skeletal muscle cells, 
methylglyoxal induces alterations of IRS-1 proteins and this represents 
a new concept of negative regulation of insulin signaling as they appear 
to be essentially based on chemical modifications of IRS proteins 
induced by a metabolite (Van Obberghen 2006).  
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Figure 6  Mechanisms b y which  intr acellular pr oduction of a dvanced gly cation 
end-product (AGE) precursors damages cells. Covalent modification of intracellular 
proteins by dicarbonyl AGE precursors alters several cellular functions. Modification of 
extracellular matrix proteins causes abnormal interactions with other matrix proteins 
and with integrins. Modification of plasma proteins by AGE precursors creates ligands 
that bind to AGE receptors, inducing changes in gene expression in different cells 
type. 
 
 
6.3 Glucotoxicity, increased flux through the hexosamine p athway 
and insulin resistance. 
The HSP is a relatively minor branch of the glycolytic pathway, 
encompassing about 3% of total glucose utilezed (Marsahll 1991).  
Entry into the HSP is catalyzed by the first and rate limiting enzyme 
glutamine:fructose-6-phosphate (F-6-P) amidotransferase (GFAT), 
which converts F-6-P and glutamine to glucosamine-6-phosphate 
(GlcN-6-P) and glutamate. Subsequent steps metabolize GlcN-6-P to 
UDP-N-acetylglucosamine (UDP-GlcNAc), UDP-N-acetylgalactosamine 
(UDP-GalNAc) and CMP-syalic acid, essential building blocks of the 
glycosyl side chains of glycoproteins, glycolipids, proteoglycans and 
gangliosides (Figure 7). UDP-GlcNAc is of particular interest because a) 
quantitatively it is the major end product of the HSP, b) it is an allosteric 
feedback inhibitor of GFAT, which regulates glucose entry into the 
pathway and c) it is the obligatory substrate of O-GlcNAc transferase 
(OGT). The latter is a cytosolic and nuclear enzyme, which catalyzes a 
reversible post-translational protein modification, whereby N-
acetylglucosamine (GlcNAc) is transferred in O-linkage to specific 
 19
serine/threonine residues of numerous proteins (Buse 2006). The sites 
of O-GlcNAc modification (O-GlcNAcylation) are often identical or 
adjacent to known phosphorylation sites, suggesting a regulatory 
function (Comer 2001). Functional significance of O-GlcNAcylation has 
been reported for several proteins (Wells 2001), including the 
transcription factors Sp1 (Buse 2006), c-myc (Kamemura 2002), CREB 
(Lamarre-Vincent N 2003) and PDX-1 (Gao Y 2003), as well as 
cytosolic and nuclear enzymes, e.g. glycogen synthase (Parker 2004; 
Parker 2003) and RNA polymerase II (Comer 2001). Of particular 
interest in the context of insulin resistance is that insulin receptor 
substrates (IRS)-1 and 2 (Andreozzi 2004; Buse  2006) and probably 
also GLUT4 (Buse 2002) are subject to O-GlcNAcylation. The 
reversible, O-GlcNAc modification of proteins has been suggested by 
many investigators as a mechanisms by which increased HSP activity 
could cause insulin resistance.  
A role for excess glucose flux via HSP in insulin resistance was first 
proposed by Marshall et al in 1991, based on experiments using 
isolated rat adipocytes (Buse 2006). In this system, pre-exposure of the 
cells to insulin and high glucose act synergistically to induce resistance 
of glucose transport to subsequent acute stimulation by insulin. 
There is considerable evidence indicating that increased activity of the 
HSP can cause insulin resistance in cell culture models and in rodents 
in vivo. In the model mentioned above, where sustained exposure to 
high glucose in the presence of insulin caused insulin resistance in 
adipocytes, treatment of the cells with inhibitors of GFAT activity 
prevented this effect. Furthermore, glucosamine, (GlcN) which enters 
the HSP bypassing GFAT, also caused insulin resistance. The effect of 
GlcN infusions on the development of insulin resistance in rodents, 
undergoing insulin clamp studies has been extensively studied (Buse 
2006; Rossetti 1995). Rossetti reported in 1995, that infusion of GlcN 
increased the concentrations of UDP-GlcNAc in muscle, and markedly 
decreased insulin stimulated total body glucose utilization in healthy 
control, but not in diabetic rats, which were already insulin resistant 
(Rossetti 1995). Previous studies demonstrated that in vitro treatment of 
isolated muscles with GlcN inhibited the insulin response of glucose 
transport, without affecting insulin receptor and GLUT4 expression 
(Robinson 1993). Sustained hyperglycemia, which causes insulin 
resistance, also increased UDP-HexNAc concentrations in muscles 
(Robinson 1995). Transgenic mice overexpressing GFAT in skeletal 
muscle and adipocytes develop peripheral insulin resistance as they 
age, as determined by euglycemic insulin clamp studies. GLUT4 
expression in muscle is unchanged, and the insulin resistance likely 
represents defective translocation of GLUT4 to the muscle cell 
membrane, or a defect in docking and/or incorporation of GLUT4 into 
the plasmalemma of muscle in vivo (Hebert 1996). The mechanism by 
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which GlcN or the increased glucose flux via the HSP determines 
insulin resistance is still debated. Several studies, performed both “in 
vitro” and “in vivo” , showed a defect in GLUT4 translocation in 
response to insulin (Buse 2006)  or a block in signal transduction 
downstream of PI-3-kinase, at the level of Akt activation (Buse 2006). 
Alternatively it has been well documented that increased glucose flux 
into cells and via HSP promotes the O-GlcNAc modification on Ser/Thr 
residues of selected proteins, and this process is believed to mediate 
the effects of HSP. The process is catalyzed by a cytosolic/nuclear 
enzyme, O-GlcNAc transferase (OGT), which is responsive to UDP-
GlcNAc concentrations in the physiological range (Buse 2006). 
Numerous investigators have reported increased O-GlcNAc 
modification of proteins, (demonstrated immunologically), in tissue 
culture or in experimental animals, under conditions of insulin 
resistance where glucose flux into cells was chronically increased, or 
after exposure to GlcN or in cells overexpressing GFAT (Buse 2002; 
McClain 2002; Patti 1999; Rossetti 2000; Yki-Jarvinen 1998). However, 
the proteins were only rarely identified, and a causal connection was 
not established. More recently, more direct evidence has emerged. The 
enzyme, which removes the O-GlcNAc modification from Ser/Thr, is O-
GlcNAcase, has been cloned (Buse 2006) and a pharmacological 
agent, which is a competitive inhibitor of O-GlcNAcase has been 
developed, (PUGNAC) (Haltiwanger 1998). When 3T3-L1 adipocytes 
are incubated with PUGNAC, the removal of O-GlcNAc from proteins is 
inhibited, and the cells develop insulin resistant glucose transport, as 
well as inhibition of insulin stimulated Akt activation.  
There are a very few clinical studies examining the role of HSP in 
insulin resistance. Yki Jarvinen reported in 1996 that GFAT activity was 
increased in muscle biopsies obtained from insulin resistant patients 
with type 2 diabetes (Yki-Jarvinen 1996). Two papers studied the effect 
of GlcN infusions on insulin responsiveness in humans. In one paper, 
minimal effects were observed, i.e. blunted insulin secretory response 
in response to a glucose load and mildly increased fasting glucose 
levels (which could represent the known inhibitory effect of GlcN on islet 
glucokinase), but in neither paper were any effects noted on glucose 
utilization during an euglycemic insulin clamp or on hepatic glucose 
production. Thus, humans may be less sensitive to the insulin 
resistance promoting effect of GlcN than rodents (Pouwels 2001). The 
role of the HSP as a determinant in the development of insulin 
resistance is more problematic. While it is clear that overexpression of 
GFAT or of O-GlcNAc transferase can produce insulin resistance in 
mice, the requirement for increased HSP flux for the establishment of 
glucose induced insulin resistance has been questioned. Nevertheless, 
with the rapidly increasing knowledge of the O-GlcNAc modification of 
selected proteins and their regulation, and the fact that uncontrolled 
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diabetes affects this process, it seems likely that a role for the HSP in 
the development of the metabolic syndrome and insulin resistance will 
prevail. 
 
 
 
 
Figure 7  The he xosamine pathw ay. The glycolytic intermediate fructose-6-
phosphate (Fruc-6-P) is converted to glucosamine-6-phosphate by the enzyme 
glutamine:fructose-6 phosphate amidotransferase (GFAT). Intracellular glycosylation 
by the addition of N acetylglucosamine (GlcNAc) to serine and threonine is catalysed 
by the enzyme O GlcNAc transferase (OGT). Increased donation of GlcNAc moieties 
to serine and threonine residues of transcription factors such as Sp1, often at 
phosphorylation sites, increases the production of factors as PAI-1 and TGF-1. AZA, 
azaserine; AS-GFAT, antisense to GFAT.  
 
 
 
6.4 Glucotoxicity , Endoplasmic Reticulum stre ss and insulin 
resistance.  
The endoplasmic reticulum (ER) is the principal site of protein 
synthesis, and together with the Golgi apparatus, it facilitates transport 
and release of correctly folded proteins. Under conditions of cellular 
stress leading to an impairment of ER function, proteins are unable to 
fold properly and accumulate in the ER lumen. It is due to these 
unfolded or misfolded proteins that the ER has evolved a coping system 
known as the Unfolded Protein Response (UPR) (Kaufman 1999; Liang  
2006). Cellular stresses that may elicit UPR activation include glucose 
and energy deprivation, increased protein synthesis, inhibition of protein 
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glycosylation and imbalance of ER calcium levels (Mori 2000; 
Oyadomari 2002). In mammalian cells, at least four functionally distinct 
responses have been identified and three ER-resident transmembrane 
proteins have been described as primary sensors and transducers of 
the UPR: the double-stranded RNA-activated protein kinase-like ER 
kinase (PERK), the inositol requiring-1 (IRE-1) and the activating 
transcription factor 6 (ATF6) (Shi 1998; Wang 1998; Yoshida 1998). 
The first response, mediated by PERK, is translational attenuation, to 
reduce the load of new protein synthesis and prevent further 
accumulation of unfolded proteins (Harding 2002). The second 
response is upregulation of genes encoding ER chaperone proteins 
such as the immunoglobulin heavy chain-binding protein/glucose-
regulated protein 78kDa (BiP/GRP78) and the glucose-regulated 
protein 94kDa (GRP94), to increase the ER protein-folding capacity 
(Yoshida 1998; Kozutsumi 1988). The third response is transcriptional 
activation of genes involved in the degradation of misfolded protein in 
the ER by the ubiquitin-proteasome system, called the ER-associated 
degradation (Travers 2000). The fourth response is apoptosis, which 
occurs when severe and prolonged ER stress impairs ER functions, to 
protect the organism by eliminating the damaged cells (Oyadomari 
2002) (Figure 8). 
ER stress plays an important role in several human diseases, including 
Type 2 diabetes; indeed, recent studies reported that ER stress is 
involved both in pancreatic beta-cell dysfunction (Kaneto 2005; 
Scheuner 2001; Shi 2003) and peripheral insulin resistance (Nakatani  
2005; Ozcan 2004). While the consequences of ER stress have been 
widely studied in adipose tissue and liver, ER stress in skeletal muscle, 
the major site of glucose disposal, has not received equal attention. The 
hexosamine biosynthetic pathway (HBP) is a minor glucose metabolic 
pathway that metabolizes ~3% of glucose entering the cell, and the final 
product of this pathway, UDP-N-acetylglucosamine, as other nucleotide 
hexosamines, are used in the ER as substrates for protein glycosylation 
(Rossetti 2000;  Pirola 2004). Although quantitatively utilising a small 
fraction of glucose, HBP is an important contributor to the insulin-
resistant state. Several studies showed, indeed, that chronic exposure 
to glucosamine (GlcN) - a precursor of the HBP - impairs insulin 
responsiveness, thus contributing to the formation of an insulin-resistant 
state in cultured human skeletal muscle cells and rat adipocytes (Pirola 
2004) as well as in vivo (Rossetti 1995). However, the precise 
mechanisms by which GlcN induces insulin-resistance have not been 
conclusively established in these studies. 
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Figure 8 Mechanism o f UPR activation. In mammalian cells, the UPR is 
characterized by transcriptional activation of chaperone and protein-folding genes, 
regulation of growth arrest and apoptosis genes, and repression of global protein 
synthesis. The ER chaperone protein BiP/GRP78 acts as the principal regulator of 
three ER-resident transmembrane proteins, PERK (double-stranded RNA-activated 
protein kinase-like ER kinase), IRE-1 (inositol requiring-1) and ATF6 (activating 
transcription factor 6) which are primary sensors and trasducers of the UPR. 
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Aim of the study 
 
Recently it has been demonstrated that chronic hyperglycaemia 
induces ER stress in cultured pancreatic  cells, causing the increase in 
Bip/GRP78 and CHOP/GADD153 and activating SREBP-1 (Sterol 
Regulatory Element Binding Protein-1. In vivo and in vitro experiments 
established that chronic hyperglycaemia in diabetic humans and rats 
could induce or worsen the insulin- resistance state and, in some cases, 
the process seem to be linked to the UPR activation. Glucosamine 
(GlcN)  is one of the molecule that mediate glucotoxicity effects. Indeed 
recent data suggest that in hyperglycaemia conditions, glucose, through 
GlcN production, induces insulin-resistance; although the precise 
mechanism by which it happens is not yet clear. Recent evidences 
show that high GlcN levels induce ER stress in cultured hepatocytes, 
monocites and smooth muscle cells (Werstuck 2006). Even if different 
studies support the role of ER stress in the alteration of insulin 
sensitivity in the liver and adipose tissue there are few evidences 
regarding the effect of ER stress in skeletal muscle. Thus, in this work 
we sough to evaluate the possible role of ER stress in the induction of 
insulin resistance by glucosamine in skeletal muscle cells. 
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Methods 
 
Materials. DMEM, FBS, FCS, L-glutamine and BSA were from 
Invitrogen (Paisley, UK). Thapsigargin (Thap), GlcN, 4-phenyl butyric 
acid (PBA), N-Acetyl Cysteine (NAC), were from Sigma-Aldrich (St. 
Louis, MO, USA). Mn(III)tetrakis(4-benzoic acid) porphyrin chloride 
(MnTBAP) and tauroursodeoxycholic acid (TUDCA) were from 
Calbiochem (San Diego, CA, USA). Other reagents were as follows: 
Ultroser G (Pall Biosepra, Cergy, France),  [14C]2-deoxy-glucose (2-DG) 
(Perkin Elmer, Waltham, MA, USA), insulin (Novo Nordisk, Bagsværd, 
Denmark),  GLUT4 (Abcam, Cambridge, UK), myocyte enhancer factor 
2 a (MEF2A), peroxisome proliferators-activated receptor- coactivator 
1  (PGC1 eukaryotic translation initiation factor 2 (eIF2and 
phospho-eIF2 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), siRNA and siPORTTM NeoFXTM Transfection Agent (Applied 
Biosystems, Carlsbad, CA, USA). Azaserine (Aza), O-(2-Acetamido-2-
deoxy-D-glucopyranosylidenamino) and N-phenylcarbamate (PUGNAc) 
were obtained from Sigma-Aldrich (St. Louis, MO, USA). ApoSENSOR 
ADP/ATP Ratio Assay Kit was from BioVision, Inc (Montain View, CA, 
USA). 
 
Cell culture procedures. Human cell cultures from lean subjects were 
established as described in (Bergstrom 1975; Gaster 2001) (Table 3). 
Cells were cultured in DMEM supplemented with 2% (vol/vol) FCS, 2% 
(vol/vol) Ultroser G, and antibiotics human myotubes were allowed to 
differentiate under physiological conditions of insulin (25 pmol/l) and 
glucose (5.5 mmol/l) for 4 days. L6 skeletal muscle myoblasts were 
grown in DMEM supplemented with 10% (vol/vol) FBS, 2 mmol/L L-
glutamine, and antibiotics L6 myotubes were allowed to differentiate as 
described in (Cassese 2008). 
 
2-DG uptake.  2-DG uptake was measured as reported previously 
(Miele 2003). Briefly, myotubes were incubated in DMEM supplemented 
with 0.25% (wt/vol) BSA for 24 h in the presence or absence of different 
compounds. Cells were incubated in glucose-free HEPES buffer [5 
mmol/L KCl, 120 mmol/L NaCl, 1.2 mmol/L MgSO4, 10 mmol/L 
NaHCO3, 1.2 mmol/L KHPO4, and 20 mmol/L HEPES, pH 7.8, 2% 
(wt/vol) albumin], then stimulated with 100 nmol/L insulin for 30 min, 
supplemented during the final 10 min with 0.2 mmol/L [14C]2-DG. Cells 
were then solubilized and the 2-DG uptake was quantified by liquid 
scintillation counting.  
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RNA extraction and Real-time RT-PCR  
Total cellular RNA was isolated from human and rat muscle cells using 
the RNeasy kit (QIAGEN Sciences, Germany). For Real-time RT-PCR 
analysis, 1 g of cell RNA was reverse-transcribed using Superscript III 
Reverse Transcriptase (Invitrogen CA). PCR reactions were analyzed 
using Platinum SYBR Green qPCR Super-UDG using an iCycler IQ 
multicolour Real Time PCR Detection System (Biorad, CA). All 
reactions were performed in triplicate and GAPDH was used as an 
internal standard. 
 
Western Blot analysis . For Western blot analysis, cells were 
solubilized in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10 
mM EDTA, 10 mM Na
2
P
2
O
7
, 2 mM Na
3
VO
4
, 100 mM NaF, 10% 
glycerol, 1% Triton X-100, 1 mM phenylmethylsulfonylfluoride, 10 μg/ml 
aprotinin) for 2 h at 4°C. Cell lysates were clarified by centrifugation at 
5,000 x g for 20 min, separated by SDS-PAGE (or firstly 
immunoprecipitated), and transferred into 0.45-μm Immobilon-P 
membranes (Millipore, Bedford, MA). Upon incubation with primary and 
secondary antibodies, immmunoreactive bands were detected by ECL 
according to the manufacturer's instructions. 
 
 
ATP Measurement. ATP concentrations were determined according to 
manufacturer’s recommendations. Briefly, differentiated myotubes were 
treated or not with different concentrations of GlcN (5, 7.5, 10, 20 and 
40 mmol/L) for 24 h. Cells were then incubated with the Nucleotide 
Releasing Buffer for 5 minutes at room temperature and solubilised. 
After adding the ATP Monitoring Enzyme in the cell lysates ATP 
concentrations were quantified in a luminometer.  
 
Chromatin Immunoprecipitation Assay . ChIP assay was performed 
as reported (Ungaro 2008). Vehicle- or treated myotubes were fixed 
with 1% (vol/vol) formaldehyde at 37 °C. The fixed cells were lysed in a 
SDS lysis buffer [1% (wt/vol) SDS, 10 mmol/L EDTA, and 50 mmol/L 
Tris–HCl, pH 8.1], incubated on ice, and sonicated to shear DNA. 
Sheared chromatin samples were taken as input control or used for 
immunoprecipitation with anti-MEF2A, anti-PGC1 or non-immune 
antibodies. DNA fragments were recovered and were subjected to Real 
Time RT-PCR amplification by using specific primers for the analyzed 
regions.  
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ATF6 siRNA-mediated Knockdown.  Cells were transfected with 5 
nmol/L of siRNA negative control and siRNA-Atf6 Sense 
(GCUUGUCAGUCACGAAAGAtt) and Antisense 
(UCUUUCGUGACUGACAAGCag) according to manufacturer’s 
recommendations and processed 48 h after transfection. 
Statistical procedur es. Data were analysed with Statview software 
(Abacus-concepts) by one-factor analysis of variance. p values of less 
than 0.05 were considered statistically significant.  
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Results 
  
To investigate the role of GlcN in the ER stress induction, differentiated 
L6 skeletal muscle cells were treated with different concentrations of 
GlcN. The classical ER stress inducer Thap, an inhibitor of SERCA 
ATP-ases, was used as control of ER stress induction (Liang 2006). In 
L6 myotubes, Thap induced a 17-fold increase of the chaperon 
Bip/grp78 mRNA (Figure 9a), indicating that our cellular model was 
sensitive to ER stress. Bip/grp78 mRNA levels were increased also by 
GlcN, with a maximal expression observed at 10 mmol/L GlcN for 24 h 
(Figure 9b). Interestingly, pre-treatment of cells with azaserine, a non-
specific but commonly used inhibitor of the Glutamine:fructose 6 
phoshate amidotransferase (GFAT) (Marshall 1991; Buse 2006), the 
rate-limiting enzyme of the HBP, prevented high glucose (HG)-induced-
ER stress (Figure 9e). In addition, treatment of cells with the peptide O-
GlcNAc-β-N acetylglucosaminidase inhibitor PUGNAc, did not increase 
Bip/grp78 mRNA levels, suggesting that enhanced O-linked 
glycosylation was not responsible for the induction of ER stress (Figure 
9e). To evaluate whether GlcN-induced ER stress could be mediated by 
oxidative stress, L6 myotubes were pre-treated with two anti-oxidants, 
the glutathione precursor NAC and the superoxide dismutase mimetic 
MnTBAP.  Pre-treatment of cells with both NAC and MnTBAP did not 
affect GlcN-induced Bip/grp78 mRNA increase, suggesting that GlcN-
induced ER stress was not dependent from oxidative stress in skeletal 
muscle cells (Figure 9b). Then we evaluated the effects of different 
concentrations of GlcN on ATP intracellular levels. GlcN depleted ATP 
pool only at the highest concentrations, suggesting that GlcN-induced 
ER stress was not dependent from ATP depletion in skeletal muscle 
cells (Figure 9f). As expected, xylose did not induce Bip/grp78 mRNA 
increase even at high concentrations (Figure 9b), thus excluding an 
osmotic stress effect caused by treatments. Time-course analysis with 
7.5 mmol/L GlcN, showed that Bip/grp78 expression was significantly 
increased as early as 2 h after the treatment and raised up to 16 h 
(Figure 9c). To investigate whether chemical chaperones could prevent 
GlcN induced ER stress, we analyzed Bip/grp78 mRNA in L6 myotubes 
treated with GlcN in the presence of either 10 mmol/L PBA, a low 
molecular weight non-specific chemical chaperone known to stabilize 
protein conformation and to improve ER folding capacity (Ozcan 2006), 
or 5 mmol/L TUDCA, a bile  acid derivative that also modulates ER 
function (Ozcan 2006). Both PBA and TUDCA almost completely 
prevented the effect of GlcN on Bip/grp78 mRNA (Figure 9d). These 
data suggest that GlcN is able to induce ER stress in skeletal muscle 
cells and that this effect is prevented by chemical chaperones. 
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Figure 9 GlcN induces BIP/GRP78 i n L6 myotu bes. a–e Bip/grp78 mRNA was 
determined by real-time RT-PCR analysis of total RNA isolated from myotubes, using 
Gapdh as internal standard. mRNA levels in treated cells are relative expression units 
(REU) to those in control (C; mean ± SD; n = 8). ***p < 0.001. a L6 cells were treated 
with 0.5 µmol/l Thap for 30 min, followed by 24 h without Thap. b L6 cells were 
pretreated or not with 5 mmol/l NAC or with 1 mg/ml MnTBAP for 2 h and then 
cultured in the presence of GlcN or xylose, as indicated, for 24 h. c Time course of 
Bip/grp78 mRNA in L6 cells cultured with 7.5 mmol/l GlcN for the indicated times. d L6 
cells were pretreated or not for 1 h with 10 mmol/l PBA or 5 mmol/l TUDCA and then 
treated with 7.5 mmol/l GlcN for 24 h. e L6 cells were pre-treated or not with 20 mol/L 
Aza for 20 min and then cultured in presence of 25 mmol/L glucose or 100 mol/L 
PUGNAc, as indicated above, for 24 h. f L6 cells were treated or not with different 
concentrations of GlcN (5, 7.5, 10, 20 and 40 mmol/L) for 24 h. ATP content in treated 
cells is relative to those in control cells in which is expressed as 100% (mean±SD; 
n=3). ***, P < 0.001.     
 
 
To verify whether GlcN was able to induce UPR activation, L6 
myotubes were treated with GlcN or Thap and different markers of UPR 
activation were analyzed. The mRNA levels of the spliced active form of 
the X-box binding protein-1 (Xbp-1 s) increased significantly following 
both Thap (Figure 10a) and GlcN treatments (Figure 10b). Time-course 
experiments showed that the increase of Xbp-1 s peaked at 8 h of GlcN 
treatment and remained higher than basal level up to 24 h (Figure 10b).  
In addition, also the mRNA levels of the total form of Xbp-1 (Xbp-1 t) 
and Atf6 were significantly increased upon both Thap (Figure 10c, e) 
and GlcN treatments (Figure 10d, f). Furthermore, phosphorylation of 
eIF2 was evident as early as 30 min after both GlcN and Thap 
treatment, and it persisted up to 24 h following GlcN treatment (Figure 
10g). These data suggest that GlcN caused UPR activation in L6 
myotubes.  
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Figure 10 GlcN induces UPR activation in L6 myotubes. a–g L6 cells were treated 
with 0.5 µmol/l Thap for 30 min, followed by 24 h without Thap, or with 7.5 mmol/l 
GlcN for the indicated times (a–f). Xbp1 s (a, b), Xbp1 t (c, d) and Atf6 (e, f) mRNAs 
in treated cells are relative expression units (REU) to those in control (C; mean ± SD; 
n = 7) and were determined by real-time RT-PCR analysis, using Gapdh as internal 
standard. *p < 0.05; ***p < 0.001. g L6 cells treated with 0.5 µmol/l Thap for 30 min, 
followed by 24 h without Thap (left), or with 7.5 mmol/l GlcN (right) for the indicated 
times, were solubilised and equal amounts of proteins (80 µg per sample) were 
analysed by western blotting using phospho-eIF2α Ser51 and eIF2α specific 
antibodies (n = 5)  
 
 
To investigate the effect of GlcN-induced ER stress on the insulin 
sensitivity of skeletal muscle cells, insulin-induced glucose uptake was 
evaluated in L6 myotubes treated with GlcN for 24 h. GlcN treatment 
reduced the capability of L6 cells to uptake the glucose analogue 2-DG 
upon insulin stimulation, compared to control cells (Figure 11a). Similar 
results were obtained when cells were treated with Thap (data not 
shown) and HG (Figure 11b). To verify the hypothesis that GlcN may 
impair glucose uptake in L6 cells through ER stress induction, we 
analyzed insulin-induced glucose uptake in cells treated with GlcN in 
the presence of PBA or TUDCA. Interestingly, both PBA and TUDCA 
prevented GlcN (Figure 11a) and HG (Figure 11b) effects on insulin-
stimulated glucose uptake suggesting that ER stress caused insulin 
resistance in skeletal muscle cells. 
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Figure 11 Effect of  ER stress on 2-DG glucose uptake and G lut4 expression in 
L6 myotubes. a-b L6 cells were pre-treated or not for 1 h with 10 mmol/L PBA or 5 
mmol/L TUDCA and then treated with 7.5 mmol/L GlcN or 25mol/L Glu for 24 h. 2-DG 
uptake was measured following 30 min of insulin stimulation (mean±SD; n=5). **, P < 
0.01; ***, P < 0.001.  
 
 
We then evaluated GlcN effects on the expression of Glut4, since it is 
the main glucose transporter responsible for insulin-mediated glucose 
uptake in muscle (Klip 2009). Time-course analysis showed that Glut4 
mRNA levels were significantly decreased as early as 6 h after GlcN 
treatment, and were reduced by about 50% after 16 h of treatment 
(Figure 12a). Glut4 mRNA levels did not show any significant variation 
when L6 myotubes were treated with GlcN in the presence of PBA 
(Figure 12b). In addition, the GlcN-dependent decrease of Glut4 mRNA 
expression was paralleled by a similar reduction of Glut4 protein levels 
and this was also prevented by pre-treatment with PBA (Figure 12c). As 
for GlcN, both Thap and HG treatment (data not shown), induced a 
significant decrease of both Glut4 protein and mRNA levels compared 
to control cells. These data indicated that GlcN and HG reduced Glut4 
expression through the induction of ER stress. 
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Figure 12 GlcN effect on Glut4 e xpression (a-c) Glut4 mRNA was determined by 
real-time RT-PCR analysis of total RNA isolated from myotubes, using Gapdh as 
internal standard. mRNA levels in treated cells are relative to those in control 
(mean±SD; n=5). ***, P < 0.001. (a) Time-course of Glut4 mRNA in L6 cells treated 
with 7.5 mmol/L GlcN for the indicated times. (b) Glut4 mRNA was detected in L6 cells 
pre-treated or not with 10 mmol/L PBA for 1 hour, and than treated with 7.5 mmol/L 
GlcN for 24 h. (c) L6 cells pre-treated or not with 10 mmol/L PBA for 1 hour, and than 
treated with 7.5 mmol/L GlcN for 24 h, were solubilised and equal amounts of proteins 
(80 g/sample) were analyzed by WB using GLUT4 specific antibody (n=5). A 
representative autoradiograph is shown.  **, P < 0.01.  
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Actinomycin D treatment did not further decrease Glut4 mRNA upon 
GlcN treatment, suggesting that GlcN-induced ER stress determined a 
transcriptional inhibition of Glut4 in skeletal muscle cells, without 
affecting its mRNA stability (data not shown). Then, to gain further 
insight into the mechanisms leading to Glut4 reduced transcription, we 
analyzed the expression of genes relevant to Glut4 transcriptional 
regulation by real-time RT-PCR analysis. Time-course experiments 
showed that GlcN caused a significant reduction of the Mef2a mRNA 
expression as early as 6 h after the treatment with a 60% reduction 
upon 16 h (Figure 13a). Similarly, MEF2A coactivator peroxisome 
Pgc1 was reduced by 50 % upon 16 h of treatment when compared to 
control cells (Figure 13c). As for GlcN, both Thap (data not shown) and 
HG treatment (data not shown) induced a significant decrease of Mef2a 
and Pgc1 expression levels. L6 cells treated with GlcN in the presence 
of PBA exhibited no differences in the mRNA levels of both Mef2a (Fig. 
13b) and Pgc1 (Figure 13d) when compared to control cells, 
confirming that also Mef2a and Pgc1 reduced expression was 
dependent on GlcN-induced ER stress. To establish whether the 
reduction of Mef2a and Pgc1 expression induced by ER stress was 
paralleled by a reduced binding of these two proteins to the Glut4 
promoter, we performed ChIP and ReChip experiments in L6 cells 
treated with GlcN. Mef2a binding to Glut4 promoter showed a 60% 
decrease upon GlcN treatment compared to control cells (Figure 13e). 
Similarly, Pgc1 indirect binding to Glut4 promoter measured by 
ReChip assay was reduced by 40% upon GlcN treatment compared to 
control cells (Figure 13f). These data indicate that GlcN-induced ER 
stress causes the transcriptional inhibition of Glut4 at least in part by 
reducing both Mef2a and Pgc1 mRNA levels and their binding to the 
Glut4 promoter. 
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Figure 13 Effect of ER stress on Mef2a and Pgc1 mRNA expression and Glut4 
promoter binding in L6 myotubes. (a-d) Mef2a and Pgc1 mRNAs were determined 
by real-time RT-PCR analysis, using Gapdh as internal standard. mRNA levels in 
treated cells are relative to those in control (mean±SD; n=4). *, P < 0.05; **, P < 0.01; 
***, P < 0.001.  (a) Time-course of Mef2a mRNA in L6 cells treated with 7.5 mmol/L 
GlcN for the indicated times. (b) Time-course of Pgc1 mRNA in L6 cells treated with 
7.5 mmol/L GlcN for the indicated times. (c) Mef2a mRNA was detected in L6 cells 
pre-treated or not with 10 mmol/L PBA for 1 hour, and than treated with 7.5 mmol/L 
GlcN for 24 h. (d) Pgc1 mRNA was detected in L6 cells pre-treated or not with 10 
mmol/L PBA for 1 hour, and than treated with 7.5 mmol/L GlcN for 24 h. (e-f) Soluble 
chromatin was prepared from L6 cells vehicle treated or treated with 7.5 mmol/L GlcN 
for 24 hours as described in Methods and immunoprecipitated (IP) with MEF2A 
antibody (e) or re-immunoprecipitated (ReIP) with PGC1 antibody (f). IP were then 
amplified by Real Time RT-PCR analysis using specific primers for the analyzed 
regions (mean±SD; n=3). ***, P < 0.001. 
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To understand the mechanisms involved in the transcriptional inhibition 
of Glut4, Mef2a and Pgc1 by ER stress, we sought to evaluate the role 
of the activating transcription factor 6 (Atf6), a gene whose expression 
has been reported to be up-regulated during ER stress and may cause 
inhibition of gene expression via up-regulation of the orphan nuclear 
receptor small heterodimer partner (SHP) in pancreatic beta-cells (Seo 
2008). To test the hypothesis that the overexpression of ATF6 is 
sufficient to impair Glut4 expression, we generated L6-cell lines stably 
overexpressing Atf6 (Figure 14a). In Atf6 overexpressing cells, Glut4 
mRNA levels were reduced by 60% in basal condition (Figure 14b), and 
were further decreased by 75% upon GlcN treatment (Figure 14b). Atf6 
overexpression also induced similar decreases of Mef2a and Pgc1 
expression compared to control cells (data not shown). Treatment with 
a specific small interference RNA (siRNA) for Atf6 significantly inhibited 
the mRNA level of Atf6 both in untreated and GlcN treated cells (Figure 
14c). As expected, the transfection of cells with a siRNA for a non 
eukaryotic gene, used as negative control, did not affect the up-
regulation of Atf6 induced by GlcN (Figure 14c). In addition, the siRNA 
for Atf6 completely prevented GlcN-induced down-regulation of Glut4, 
Mef2a and Pgc1 (Figure 14d). L6 cells were also transfected with a 
siRNA for Shp. As expected, the treatment with the siRNA for Shp 
significantly inhibited the mRNA level of Shp both in untreated and GlcN 
treated cells (data not shown); by contrast, it was not able to prevent 
the GlcN-induced down-regulation of Glut4, Mef2a and Pgc1 (data not 
shown). These data indicate that the activation of Atf6 is responsible for 
the impairment of Glut4 expression during GlcN-induced ER stress 
through a mechanism independent from Shp activation.                                          
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Figure 14 Role of Atf6 o n GlcN-induced ER stress in L6 myotube s. (a-b) L6 cells 
were stably transfected with Atf6 cDNA. Atf6 (a) and Glut4 (b) mRNAs in clones are 
relative to those in untrasfected cells (L6) and were determined by real-time RT-PCR 
analysis using Gapdh as internal standard (mean±SD; n=3). ***, P < 0.001.  (a) Atf6 
mRNA was detected in several clones. Two clones (termed clones a and d) 
overexpressing Atf6 by 2.5- and 3.5-fold were further characterized. (b) Glut4 mRNA 
was detected in L6 cells untrasfected or stably transfected with Atf6 cDNA treated with 
7.5 mmol/L GlcN for 24 h. (c-d) L6 cells were transiently transfected with siRNA-Atf6 
or with a negative control siRNA, and than treated with 7.5 mmol/L GlcN for 24 h. 48 h 
upon transfection total RNA was extracted from transfected and non transfected cells. 
mRNAs for Atf6 (c), Glut4, Mef2a and Pgc1  (d) in treated cells are relative to those 
in control cells and were determined by real-time RT-PCR analysis using Gapdh as 
internal standard (mean±SD; n=3).  ***, P < 0.001. 
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Finally, to evaluate GlcN effects on human skeletal muscle cells we 
used cultured human skeletal muscle cells that display several features 
of mature skeletal muscle and that have been previously used for 
studies of muscle metabolism (Gaster 2001). In differentiated human 
muscle cells, GlcN induced a significant increase of both BiP/GRP78 
and ATF6 mRNA levels (Figure 15a, b), indicating that also the human 
skeletal muscle cells were sensitive to GlcN-induced ER stress. In 
addition, pre-treatment with PBA completely prevented the increase of 
both BiP/GRP78 and ATF6 mRNAs observed upon GlcN treatment 
(Figure 15a, b), confirming in human skeletal muscle cells the results 
obtained in the rat cells. In human myotubes GlcN treatment reduced 
the expression both of GLUT4, MEF2A and PGC1 mRNAs (Figure 
15c-e), and completely inhibited the uptake of 2DG upon insulin 
stimulation compared to control cells (Figure 15f). Furthermore, human 
myotubes treated with GlcN in the presence of PBA exhibited no 
differences in the mRNA expression of both GLUT4 and its upstream 
regulators MEF2A and PGC1 (Figure 15c-e) and a rescue of insulin-
induced 2DG uptake (Figure 15f) when compared to control cells. Thus, 
GlcN-induced ER stress impairs insulin-sensitivity in human skeletal 
muscle, at least in part by inhibiting GLUT4, MEF2A and PGC1 
expression. 
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Figure 1 5 GlcN e ffects in human myotubes. (a-f) Human myotubes were pre-
treated or not with 10 mmol/L PBA for 1 h, and than were treated with 7.5 mmol/L 
GlcN for 24 h. BIP/GRP78 (a), ATF6 (b), GLUT4 (c), MEF2A (d) and PGC1a (e) 
mRNAs were determined by real-time RT-PCR analysis of total RNA isolated from 
human myotubes, using GAPDH as internal standard. mRNA levels in treated cells 
are relative to those in control (mean±SD; n=4). **, P < 0.01; ***, P < 0.001. (f) 2-DG 
uptake was measured following 30 min of insulin stimulation (mean±SD; n=5). ***, P < 
0.001. 
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Discussion 
 
Glucose toxicity may contribute to impaired insulin action in diabetes 
(Cassese 2008). A widely accepted hypothesis, regarding the 
mechanism responsible for glucose-induced insulin resistance, is that 
glucose toxicity is mediated by increased flux of glucose into the HBP 
(Pirola 2004; Marshall 1991; Buse 2006). Other studies have shown 
that GlcN, but not HG, causes impairment of insulin-stimulated IRS-1 
tyrosine phosphorylation and phosphoinositide-3-kinase activation, and 
that defective protein kinase B activation by insulin is associated with 
glucose, but not GlcN-mediated insulin resistance, in adipocytes (Han 
2003). Nevertheless, studies in several model systems, including 
overexpression of GFAT and infusion/treatment with GlcN have 
confirmed that increased flux through HBP can lead to impaired glucose 
metabolism (Buse 2006; Ciaraldi 1999). Thus it seems likely that a role 
for the HBP in the development of the metabolic syndrome and insulin 
resistance will prevail. According to this, it has been reported that GlcN 
infusion in rats induces insulin-resistance to glucose uptake at the level 
of both the whole body and skeletal muscle (Patti 1999). Furthermore, 
GlcN induces insulin resistance in vitro in skeletal muscle (Bailey 2004) 
and adipose cells (Heart 2000), by reducing the insulin-induced glucose 
uptake. Many investigators have suggested the reversible O-GlcN 
modification of proteins as one possible mechanism by which increased 
HBP activity may cause insulin resistance and diabetes complications. 
However, the causal relationship between increased flux through HBP 
and insulin resistance has not been clearly established. Recently, it has 
been reported that elevated GlcN levels could interfere with the correct 
protein folding in the ER, inducing ER stress and impairment of cellular 
function in hepatic cells, monocytes and smooth muscle cells (Werstuck 
2006). On the other hand, it has been described that ER stress and 
UPR activation may play an important role in the pathogenesis of Type 
2 Diabetes (Sundar Rajan 2007), affecting both beta-cell 
function/survival (Kaneto 2005; Scheuner 2001; Shi 2003) and obesity-
induced peripheral insulin-sensitivity in liver and adipose tissue (Ozcan 
2004; Ozcan 2006). However, little is known about the role of ER stress 
in the development of insulin-resistance in skeletal muscle tissue. A 
very recent study hypothesized a molecular convergence of activated 
HBP and ER stress pathways leading to insulin-resistance in L6 cells 
(Srinivasan 2009). However, the causal link between O-glycosylation 
pathway and the ER stress pathway in determining insulin-resistance 
remained elusive. Indeed, cells silenced for O-linked N-
acetylglucosamine transferase (OGT), the enzyme responsible for the 
addition of UDP-N-acetylglucosamine to Ser/Thr residues of proteins, 
and treated with GlcN or HG, showed improved insulin-stimulated 
glucose uptake without any effect on ER chaperones regulation 
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(Srinivasan 2009).  In the present work, we suggest that ER stress may 
represent the molecular link between GlcN and insulin-resistance in 
skeletal muscle cells. We show that high GlcN concentrations, as well 
as the ER stress inducer Thap, cause ER stress and the activation of 
the UPR in L6 rat skeletal muscle cells, as demonstrated by increased 
expression of the chaperone Bip/grp78 and of the transcription factor 
Atf6, the phosphorylation of eIF2α and the increase of both the 
expression and splicing of the transcription factor Xbp1. Furthermore, 
ER stress and UPR activation are induced by GlcN in a model of human 
skeletal muscle cells (Gaster 2001), suggesting that both rat and human 
skeletal muscle cells are sensitive to GlcN-induced ER stress. More 
interestingly, HG also induces ER stress both in L6 cells and in human 
myotubes (data not shown). Pre-treatment of cells with azaserine, a 
non-specific but commonly used inhibitor of the GFAT (Marshall 1991; 
Buse 2006) prevented HG-induced-ER stress, suggesting that a least in 
part HG levels cause ER stress through hexosamines production. In 
addition, others (Bailey 2004) and we have shown that L6 myotubes are 
insulin-resistant upon GlcN as well as HG treatment, as demonstrated 
by the significant decrease in their capability to uptake the glucose 
analogue 2-DG upon insulin stimulation. To gain further insight into the 
mechanisms leading to insulin resistance, Bailey and Turner (Bailey  
2004) tested GlcN-induced insulin-resistance in L6 myotubes against 
three different insulin-sensitive acting agents. Neither metformin, that 
promotes insulin receptor tyrosine activity, nor peroxovanadium, a 
protein tyrosine phosphate inhibitor, nor D-pinitol, that partially mimic 
the PI3K pathway, were able to prevent GlcN-induced insulin resistance 
(Bailey 2004), suggesting that GlcN impairs insulin sensitivity with a 
mechanism different from that represented by an alteration of the 
upstream steps of insulin signalling. It has been shown that inhibition of 
insulin-stimulated glucose uptake by GlcN is due to intracellular ATP 
depletion in rat skeletal muscle (Han 2003), adipocytes (Hresko 1998) 
and chondrocytes (Shikhman 2009). However, in other cell types ATP 
depletion by exposure to sodium azide or dinitrophenol did not mimic 
the effects of GlcN to induce insulin resistance (Kang 2001). Thus ATP 
depletion is not the sole mechanism underlying all of the effects of 
GlcN. Indeed, we show that GlcN does not induce ATP depletion at the 
concentrations used for the study, suggesting that GlcN effects both on 
ER stress and insulin-resistance were not dependent from ATP 
depletion in skeletal muscle cells. Interestingly, we have found that pre-
treatment of both rat and human myotubes with PBA or TUDCA, two 
chemical chaperones known to prevent ER stress and the UPR 
activation in different cellular systems (Ozcan 2004; Ozcan 2006), 
completely prevents the effect of GlcN and HG on both ER stress 
induction and insulin-induced glucose uptake, suggesting that GlcN-
induced insulin-resistance is, at least in part, dependent by ER stress.  
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Glucose uptake into skeletal muscle is primarily mediated by GLUT4. 
Since it is well documented that insulin resistance in Type 2 diabetes 
can be associated with a marked reduction in GLUT4 expression 
(Armoni 2007) and/or translocation (Shepherd 1999), we hypothesized 
that GlcN-induced ER stress might affect GLUT4 gene transcription in 
both rat and human muscle cells. Here we show that this is the case, as 
both GLUT4 mRNA and protein levels are decreased by 50% upon 
GlcN as well as upon Thap and HG treatment. Both the human and the 
rat GLUT4 promoter are regulated through the cooperative function of 
two distinct regulatory elements, domain 1 and MEF2 domain, each 
required for the maximal transcription of GLUT4 promoter. Domain 1 
binds the transcription factor GEF (GLUT4 enhancer factor); MEF2 
domain binds transcription factor isoforms MEF2A and MEF2D (Armoni 
2007). MEF2A and GEF associate and function together to activate 
GLUT4 transcription (Knight 2003). Little is known about GEF, whilst 
the role of MEF2A as the main regulator of GLUT4 gene is well 
documented. Indeed, MEF2A reduced activity correlates with 
decreased Glut4 transcription in skeletal muscle of diabetic mice and its 
activity is completely normalised after insulin treatment (Handschin 
2003). GLUT4 transcription can also be modulated in skeletal muscle 
by other proteins, such as PGC1α (Al-Khalili 2005). PGC1α is a 
coactivator of MEF2A. Indeed, MEF2D binds PGC1 recruiting this 
transcriptional coactivator to MEF2A (Armoni 2007). Moreover, PGC1α 
expression is reduced in skeletal muscle of prediabetic and diabetic 
subjects (Patti 2003), and enhanced GLUT4 mRNA expression 
coincides with increased PGC1α mRNA in human skeletal muscle cell 
culture after treatment with rosiglitazone (Al-Khalili 2005). Our data, 
obtained both in rat and human myotubes, show that both GlcN- and 
HG-induced GLUT4 inhibition is paralleled by a significant decrease of 
both MEF2A and PGC1α mRNA expression, indicating that GlcN-
induced GLUT4 inhibition is exerted very likely at the transcriptional 
level. Furthermore, mRNA stability of those genes does not appear to 
be affected by GlcN-dependent ER stress (data not shown). These 
observations were confirmed by Chip and Re-Chip experiments 
showing a reduced binding of both MEF2A and PGC1α to Glut4 
promoter. Again, these effects appear to be mediated by ER stress 
signalling, since PBA or TUDCA pre-treatment of myotubes are able to 
prevent GLUT4, MEF2A and PGC1 inhibition following both GlcN and 
Thap treatments. These observations prompted us to consider the 
GlcN-induced insulin-resistance of skeletal muscle cells as a 
consequence of Glut4 inhibition and, therefore, reduced membrane 
translocation (data not shown). However, the contribution of additional 
components known to be relevant to insulin-resistance caused by ER 
stress in the adipocytes and skeletal muscle cells (Ozcan 2004; 
Srinivasan 2009), such as JNK activation, cannot be excluded. Different 
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proteins have been described to be activated by ER stress and to play a 
role in ER stress-mediated transcriptional repression. Very recently, 
indeed, ER stress-dependent activation of ATF6 has been reported to 
impair insulin gene expression in INS-1 pancreatic beta-cells cultured in 
high glucose conditions or treated with different ER stressors, via up-
regulation of SHP (Seo 2008). We demonstrate that the overexpression 
of Atf6 is sufficient to inhibit the expression of Glut4, Mef2a and Pgc1 
both in basal condition and upon GlcN treatment and that the silencing 
of Atf6 expression with a specific siRNA is sufficient to completely 
prevent GlcN-induced down-regulation of Glut4, Mef2a and Pgc1 This 
effect seems to be independent from the up-regulation of SHP since its 
silencing does not modify Glut4, Mef2a and Pgc1in skeletal muscle 
cells upon GlcN treatment.  
It has been recently shown that ATF6 is responsible for cystic fibrosis 
transmembrane conductance regulator transcriptional repression by 
binding to its promoter (Bartoszewski 2008). Our analysis of the minimal 
promoter region of Glut4, Mef2a and Pgc1 (GenBank accession 
numbers: NC 005109.2, NW 001084766.1 and NC 005113.2), using 
MatInspector, identified several putative binding sites for ATF6 and for 
other UPR regulatory factors. Further studies will be necessary to 
understand if ATF6 could repress Glut4, Mef2a and Pgc1a expression 
in our cell models through a similar mechanism.  
In conclusion, in this work we show that GlcN- as well as HG-induced 
ER stress cause insulin-resistance both in human and rat myotubes and 
impair GLUT4 expression and insulin-induced glucose uptake via an 
ATF6-dependent decrease of the GLUT4 regulators MEF2A and 
PGC1 Interestingly, treatment with the molecular chaperones, PBA 
and TUDCA, completely prevent HG- and GlcN-induced UPR activation 
and restore insulin sensitivity in myotubes. These findings are 
particularly relevant for the understanding of the molecular mechanisms 
of glucose-toxicity in skeletal muscle and of the consequences of ER 
stress to the pathogenesis of Type 2 Diabetes.  
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Chronic hyperglycemia promotes insulin resistance at least in
part by increasing the formation of advanced glycation end
products (AGEs). We have previously shown that in L6 myo-
tubes human glycated albumin (HGA) induces insulin resist-
ance by activating protein kinaseC (PKC). Herewe show that
HGA-induced PKC activation is mediated by Src. Coprecipi-
tation experiments showed that Src interacts with both the
receptor for AGE (RAGE) and PKC in HGA-treated L6 cells. A
direct interaction of PKC with Src and insulin receptor sub-
strate-1 (IRS-1) has also been detected. In addition, silencing of
IRS-1 expression abolishedHGA-inducedRAGE-PKC co-pre-
cipitation. AGEs were able to induce insulin resistance also in
vivo, as insulin tolerance tests revealed a significant impairment
of insulin sensitivity in C57/BL6 mice fed a high AGEs diet
(HAD). In tibialismuscle ofHAD-fedmice, insulin-induced glu-
cose uptake and protein kinase B phosphorylation were
reduced. This was paralleled by a 2.5-fold increase in PKC
activity. Similarly to in vitro observations, Src phosphorylation
was increased in tibialis muscle of HAD-fed mice, and co-pre-
cipitation experiments showed that Src interacts with both
RAGE and PKC. These results indicate that AGEs impairment
of insulin action in the muscle might be mediated by the forma-
tion of a multimolecular complex including RAGE/IRS-1/Src
and PKC.
Insulin resistance is genetically determined, but it may also
be affected by environmental conditions and by factors second-
ary to diseases (1). These acquired and secondary factors fur-
ther impair insulin action in diabetic individuals. For instance,
chronic hyperglycemia per se promotes insulin resistance (2, 3).
A number of mechanisms have been proposed to explain
hyperglycemia-induced insulin resistance. These include
abnormalities in the protein kinase C (PKC)3 signaling system
(4) and activation of the NF-B transcription factors by chron-
ically elevated glucose concentrations (5, 6). Chronic hypergly-
cemia also leads to the production of Amadori products
through the nonenzymatic glycation reactions between glucose
and reactive amino groups of serumproteins.Depending on the
protein turnover rate and glucose concentration, Amadori
products undergo further irreversible reactions to form
advanced glycation end products (AGEs). Themodifications of
proteins that lead to their glycation induce alterations in bio-
logical properties as compared with their non-glycated coun-
terparts. Several studies have shown that elevated concentra-
tions of Amadori products such as glycated albumin (GA) are
associated with diabetic atherogenesis by activating vascular
smooth muscle cells (7). GA has also been implicated in the
development of diabetic retinopathy (8) by induction of vascu-
lar endothelial growth factor expression (9, 10) and the stimu-
lation of choroidal endothelial cell proliferation (11). Finally,
GA has been shown to participate in the development of dia-
betic nephropathy by the induction of cytokines and growth
factors (12), which may themselves contribute to diabetic renal
disease (13). In addition to those endogenously formed, AGEs
are abundant in exogenous sources such as foods, especially
when prepared under elevated temperatures (14, 15). After
ingestion, 10%of preformedAGEs are absorbed into the human
or rodent circulation (16, 17), 2⁄3 of which are retained in tissues.
Also, reduced intake of dietary AGEs has been shown to
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decrease the incidence of type 1 diabetes in non-obese diabetic
mice (18) as well as the formation of atherosclerotic lesions in
diabetic apolipoprotein E-deficient mice (19). Furthermore,
Vlassara and co-workers (20) have shown that reduced AGE
intake leads to lower levels of circulatingAGEs and to improved
insulin sensitivity in db/dbmice. Several AGE-binding proteins
have been identified, including lactoferrin, galectin-3 (AGE-
R3), lysozyme, and the receptor for AGE (RAGE) (21). RAGE is
a multiligand member of the immunoglobulin superfamily and
is expressed on the surface of a variety of cell types. By their
binding to RAGE, AGEs trigger a range of cellular responses.
RAGEhas been reported to activate intracellular signals includ-
ing theMAPK cascade and the cdc42/Rac pathway (22), leading
to amplification or progression of various diseases including
diabetic vascular complications (23), inflammation (24), and
tumor growth/metastasis (25). The cytoplasmic region of
RAGE is considered to be responsible for the binding of the
signaling molecule(s) (26). It has been demonstrated that
ERK1/2 interacts with the cytoplasmic region of RAGE after
stimulation with amphoterin (27). Furthermore, recent
studies have shown that STAT5 becomes activated and
physically interacts with RAGE upon glycated low density
lipoprotein stimulation (28). However, RAGE is devoid of
intrinsic catalytic activity. Src tyrosine kinase is required for
signaling events downstream of several receptors lacking
intrinsic tyrosine kinase activity, such as cytokine receptors.
Cho et al. (29) have shown that glycated low density lipopro-
tein (LDL) activates ERK1/2 via Src-, phospholipase C
(PLC)-, and PKC-dependent pathways, whereas native and
non-glycated LDL activate ERK1/2 by an Src-independent
mechanism. It has been recently reported that in vascular
smooth muscle cells derived from insulin-resistant and dia-
betic db/db mice, RAGE expression and Src activity are
increased compared with those from control mice. Further
studies showed that the RAGE ligand S100B induced Src
activation in a RAGE-dependent manner. Moreover, in vas-
cular smooth muscle cells Src activation is necessary for the
S100B-induced RAGE downstream signaling involving sev-
eral targets such as caveolin-1, MAPKs, NF-B, and STAT3.
Interestingly, a PKC inhibitor could block S100B-induced
activation of MAPKs, suggesting a role for PKC in this event
(30). Recently, we have demonstrated that human glycated
albumin (HGA) pretreatment induces a selective activation
of PKC. Insulin receptor substrate (IRS) serine/threonine
phosphorylation by HGA-activated PKC inhibits insulin-
stimulated glucose metabolism without changes in growth-
related pathways regulated by insulin (31). However, the
intracellular signaling mechanism by which HGA induces
PKC activation remains to be determined. In this work we
report that HGA and dietary AGEs induce the formation of a
complex including RAGE, PKC, and Src in L6 cells and in
skeletal muscle from insulin-resistant HAD-fed mice,
respectively. In L6 cells HGA-mediated complex formation
requires the presence of IRS-1. We suggest that the forma-
tion of this complex may mediate the AGE-dependent inhi-
bition of insulin action in skeletal muscle cells in vitro and,
possibly, in vivo.
EXPERIMENTAL PROCEDURES
General—Media, sera, antibiotics for cell culture, and the
Lipofectamine reagent were from Invitrogen (Invitrogen).
Phospho-PKB and phospho-Src antibodies were purchased
from Cell Signaling Technology, Inc. (Beverly, MA). PKB,
IRS-1, phospho-Ser657 PKC, phospho-Tyr antibodies were
purchased fromUpstate Biotechnology, Inc. (Lake Placid, NY).
PKC, PKC, PKC, PKC, and RAGE antibodies were from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Src antibody
was from Calbiochem (EMD Chemicals, Inc. San Diego, CA).
The PKC assay system was from Promega (Madison, WI). Pro-
tein electrophoresis reagents were purchased from Bio-Rad,
and ECL reagents were from GE Healthcare. The IRS-1
ribozyme and control ribozymewere generous gifts ofM.Quon
(National InstitutesofHealth,Bethesda,MD).PP1 (4-amino-5-(4-
methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine) was from
Alexis Biochemicals (San Diego CA). Soluble RAGE was kindly
provided by A. Bierhaus (University of Heidelberg, Heidelberg,
Germany). All other chemicals were from Sigma.
Cell Culture and Transfection—The L6 skeletal muscle cells
were plated (6 103 cells/cm2) and grown in Dulbecco’s mod-
ified Eagle’smedium containing 1 g/liter glucose supplemented
with 2% (v/v) fetal bovine serum and 2 mM glutamine. Cultures
were maintained at 37 °C in a humidified atmosphere contain-
ing 5% (v/v) CO2. Under these culture conditions, L6myoblasts
spontaneously differentiate into myotubes upon confluence.
Transient transfections of IRS-1 and control ribozymes and of
the kinase-inactive Src were performed by the Lipofectamine
method according to the manufacturer’s instruction. The cells
were incubated for the appropriated times with 0.1 mg/ml of
HGAor non-glycated human serum albumin (HA) as a control.
Where indicated, cells were pretreated for 1 h with 50 M
PD98059, 30minwith 50 nMwortmannin, 2 hwith 5MPP1, or
30 min with 10 M U73122 or 5 M U73343 before the incuba-
tion with HGA. Where indicated, 50 g/ml of soluble RAGE
(sRAGE) were added together with HGA for the appropriated
times (32).
Characterization of Glycated Human Serum Albumin—Gly-
cated and nonglycated human serum albumin were purchased
from Sigma. The glycated serum albumin contained 2–5mol of
fructosamine/mol of albumin. The human glycated and nong-
lycated albumin preparations were tested for carboxymethyll-
ysine (CML) concentrations and the extent of lysine and argi-
nine modifications as already described (31). Each batch was
tested for possible insulin-like growth factor-I contamination
by IGF-I-D-RIA-CT (BioSource Europe,Nivelles, Belgium) and
the absence of endotoxin (lipopolysaccharide) by the use of
Limulus amebocyte lysates assay (Sigma). Each human glycated
albumin batch was reconstituted at 10 mg/ml with sterile PBS
and, to avoid glycoxidation, thereafter immediately frozen at
30 °C until use. The results obtained are summarized inTable
1 and show the absence of significant modifications in the
extent of free lysine and arginine residues between the two
preparations. Furthermore, the batches were found not to con-
tain IGF-I and to be bacterial endotoxin-free. The physico-
chemical properties determined for our HGA preparation
demonstrate that the effects observed in L6 myotubes are the
AGEs and Insulin Resistance
DECEMBER 26, 2008•VOLUME 283•NUMBER 52 JOURNAL OF BIOLOGICAL CHEMISTRY 36089
 by guest, on N
ovem
ber 26, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
consequence of glycated albumin present essentially as a gly-
cated Amadori product.
Immunoblotting, Overlay Blot, PKC Assay, and Determina-
tion of Diacylglycerol (DAG) Cellular Content—Cell lysates
were solubilized as described in Miele et al. (31). Mice were
sacrificed by cervical dislocation, and tibialis and soleus muscle
samples were collected rapidly and homogenized as previously
reported (33). Tissue homogenates and cell lysates were then
separated by SDS-PAGE and analyzed by Western blot as
described (34). Cell lysates immunoprecipitations were accom-
plished as described in Oriente et al. (35). Overlay blotting with
biotinylated PKC was performed as reported previously (34).
Filters were revealed by ECL and autoradiography. Upon
immunoprecipitation with anti-PKC or anti-RAGE antibod-
ies, PKC activity was assayed using the SignaTECT PKC assay
system (Promega) according to themanufacturer’s instructions
as described in Oriente et al. (35). DAG content was quantified
radioenzymatically by incubating aliquots of the lipid extract
withDAGkinase and [32P]ATP as described previously (36, 37).
Animals andTreatment—4-Week-oldC57/BL6 femalemice
(n 20) were purchased from the Charles River Laboratories
(Milan, Italy). Animals were kept under a 12-h light/12-h dark
cycle, and all experimental procedures and euthanasia
described below were approved by Institutional Animal Care
and Utilization Committee. After 1 week of adjustment, C57/
BL6 mice were randomly divided into two groups and placed
for 20 weeks on two commercially available standard rodent
diets similar in nutritional and caloric content (Table 2) but
with different AGEs content. Research Diets formula D12328
(Research Diets, Inc., New Brunswick, NJ) was used for the low
AGE diet (LAD), and PicoLab Rodent Diet 20 exposed to an
additional step of autoclaving at 120 °C for 30 min (Labdiet;
Purina Mills, St. Louis, MO) was used for the high AGE diet
(HAD) (20). Fasting blood glucose and bodyweights weremon-
itored biweekly. After 1 week of adjustment, food intake (in
grams of food) of individual mice was recorded daily for 1 week
at week 1, 11, and 22.
Skeletal muscles (quadriceps) of a group of 12 age-
matched C57/BL6 mice were injected with 50 mg/kg gly-
cated albumin (4 mice), non-glycated albumin (4 mice), or
PBS (4 mice). Another group of 12 mice were treated with
the same concentrations of glycated and non-glycated albu-
min, but the compounds were delivered by tail vein injection.
Mice were sacrificed after 24 h by cervical dislocation, and
muscle samples were collected rapidly and homogenized as
previously reported (33).
AGEs Determination, Metabolite Assays, and 2-Deoxy-D-[1-
3H]Glucose Uptake in Vivo—CML concentrations were deter-
mined by using a CML-enzyme-linked immunosorbent assay
kit as described in Miele et al. (31). Fasting and fed blood glu-
cose levels were measured with glucometer (A. Menarini Diag-
nostics, Florence, Italy). Insulin tolerance tests, glucose toler-
ance tests, and serum insulinmeasurements were performed as
previously described (33). Fasting plasma free fatty acid levels
weremeasuredwithWakoNEFACkit (WakoChemicals, Rich-
mond, VA), and triglycerides were measured with the Infinity
triglyceride reagent (Sigma-Aldrich). For analyzing glucose uti-
lization by skeletal muscle, an intravenous injection of 1Ci of
the non-metabolizable glucose analog 2-deoxy-D-[1-3H]glu-
cose (GEHealthcare) and an intraperitoneal injection of insulin
(0.75 milliunits/kg of body weight) were administered to ran-
dom-fed mice. The specific blood 2-deoxy-D-[1-3H]glucose
clearance was determined with 25-l blood samples collected
from the tail vein obtained 1, 15, and 30 min after injection as
previously reported (33).
Statistical Analysis—Data were analyzed with Statview
software (Abacus Concepts) by one-factor analysis of vari-
ance and are expressed as the means  S.D. Statistical sig-
nificance was evaluated using Student’s t test for unpaired
comparison. A value of p  0.05 was considered statistically
significant. The total area under the curve for glucose
response during the insulin tolerance tests and the glucose
tolerance tests was calculated by the trapezoidal method.
RESULTS
Role of HGA-activated Src in PKC Activation in L6 Skeletal
Muscle Cells—To investigate the molecular mechanisms of
PKC activation by AGEs, HGA-induced PKC activity was
measured in L6 cells treated with different pharmacological
inhibitors to selectively block ERK1/2, phosphatidylinositol
3-kinase, and Src. PKC activity in response to HGA was
unchanged upon treatment of L6 cells with PD98059 and wort-
mannin, which inhibit ERK1/2 and phosphatidylinositol 3-ki-
nase, respectively (Fig. 1a). At variance, preincubation with the
Src inhibitor PP1 or the expression of a dominant negative
kinase-inactive Src (SrcDN) (38) reduced by almost 70% HGA-
induced PKC activity (Fig. 1a). Therefore, the levels of Src
phosphorylation onTyr416 have been evaluated in L6myotubes
upon incubation for 24 h with HGA in the presence or absence
of either PP1 or SrcDN. Src phosphorylation was increased by
TABLE 1
Characteristics of glycated human albumin
Modification ratio of HGA was expressed as a percent of non-glycated human
albumin modifications used as control.
Non-glycated human
albumin
Glycated human
albumin
CML/mg protein 55 ng 195 ng
Lys modification (%) 100 94.9 3.2
Arg modification (%) 100 91.6 1.5
IGF-1 Undetectable Undetectable
LPS Undetectable Undetectable
TABLE 2
Characteristics of HAD and LAD
Nutrients HAD LAD
Protein (%) 20.5 18.5
Fat (%) 4.7 4.0
Carbohydrate (%) 54.8 58.6
Fiber (%) 5.5 6.0
Niacin (mg/kg) 93 55
Folic acid (mg/kg) 2.9 1.92
Pantothenic acid (mg/kg) 17 14,4
Biotin (mg/kg) 0.1 0.279
Cholin (mg/kg) 1000 1000
Vitamin A (IU/kg) 2500 4400
Vitamin D3 (IU/kg) 2200 1260
Vitamin E (IU/kg) 99 49.5
Vitamin B1 (mg/kg) 18 13.5
Vitamin B2 (mg/kg) 8 6.74
Vitamin B6 (mg/kg) 7.8 5.98
Vitamin B12 (mg/kg) 0.018 0.027
Caloric profile (kcal/g) 3.4 3.7
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HGA, but this effect was prevented by PP1 treatment (Fig. 1b)
and by overexpression of SrcDN (Fig. 1c). Furthermore, both
HGA-induced PKC (Fig. 2a) and Src (Fig. 2b) activation were
inhibited by the addition of an excess of sRAGE. To investigate
the possibility that HGA-activated Src could directly regulate
PKC activity, we first measured in L6 myotubes PKC tyro-
sine phosphorylation after HGA incubation for 24 h. As shown
in Fig. 3a, HGA induced a 3-fold increase of the tyrosine phos-
phorylation of PKC. This effect was abolished in the presence
of PP1.
Role of PLC and Phospholipase D (PLD) in HGA-induced
PKCActivation in L6 SkeletalMuscle Cells—DAG is themain
endogenous activator of classical PKCs (37).We, therefore, per-
formed thin-layer chromatography to evaluate DAG levels in
response to HGA treatment for 24 h in the presence or absence
of PP1. HGA caused a 5-fold increase (p  0.001) in the
amount of DAG in L6 skeletal muscle cells. Interestingly, the
HGAeffect onDAG levelswas significantly reduced (p 0.001)
when cells were treated with PP1 (Fig. 3b). In response to extra-
cellular stimuli, DAG is mainly generated through the action of
PLC and PLD (37). To clarify the role of PLC and PLD in HGA-
FIGURE 1. HGA-activated Src mediates PKC activation in L6 skeletal
muscle cells. a, L6 skeletalmuscle cells were incubatedwith 0.1mg/ml HA or
HGA for 24 h in the absence or in the presence of 50 M PD98059, 50 nM
wortmannin (WM), or 5MPP1. PKC activitywas assayed in the immunopre-
cipitates as described under “Experimental Procedures.” PKC activity was
measured also in L6 cells transfected with the empty vector pSG5 (mock) or
with the vector pSG5 expressing a kinase-inactive Src protein (SrcDN) and
then incubatedwith0.1mg/mlHAorHGA for 24h.Bars represent themean
S.D. of three independent experiments. b, L6 cells were incubated with 0.1
mg/mlHAorHGA for 24 h in the absence or in the presence of 5MPP1, lysed
as described under “Experimental Procedures”; lysates were then separated
by SDS-PAGE followed by immunoblotting with antibodies to phosphoty-
rosine 416 Src or total Src. The autoradiographs shown are representative of
four independent experiments. c, cell lysates of L6 skeletal muscle cells trans-
fectedwith the empty vector pSG5 (mock) orwith the vector pSG5expressing
a kinase-inactive Src protein (SrcDN) and treated as in bwere then separated
by SDS-PAGE followed by immunoblotting with antibodies to phosphoty-
rosine 416 Src or total Src. The autoradiographs shown are representative of
three independent experiments. *, statistically significant differences (*, p
0.1; **, p 0.01; ***, p 0.001).
FIGURE 2. sRAGE abrogates HGA-activated Src and PKC activation in L6
skeletal muscle cells. a, L6 skeletal muscle cells were incubated with 0.1
mg/ml HA or HGA for 24 h in the absence or in the presence of 50 g/ml
sRAGE. PKC activity was assayed in the immunoprecipitates as described
under “Experimental Procedures.” Bars represent the mean  S.D. of three
independent experiments. b, L6 skeletalmuscle cells were incubatedwith 0.1
mg/ml HA or HGA for 24 h in the presence or in the absence of 50 g/ml
sRAGE, lysed as described under “Experimental Procedures”; lysates were
then separatedby SDS-PAGE followedby immunoblottingwith antibodies to
phosphotyrosine 416 Src or total Src. The autoradiographs shown are repre-
sentative of three independent experiments. *, statistically significant differ-
ences (**, p 0.01; ***, p 0.001).
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induced PKC activation, we evaluated PKC phosphorylation
levels in L6 cells treated or not with the PLD1 inhibitor 1-buta-
nol, the PLC inhibitor U73122, and its inactive structural ana-
logue U73343. PKC activation, measured as Ser657 phospho-
rylation, was unaffected by preincubation with 1-butanol but
was abolished by treatment with U73122 (Fig. 4a). By contrast,
treatment with U73343 did not modify HGA effect on PKC
phosphorylation (Fig. 4b).
HGA-induced Association of PKC, Src, and RAGE in L6
Skeletal Muscle Cells—To investigate the ability of HGA to
induce the formation of a molecular complex between Src,
RAGE, and/or PKC, lysates from HGA-stimulated or
untreated L6myotubes were precipitatedwith anti-RAGE anti-
body and blotted with anti-Src or anti-PKC antibodies. As
shown in Fig. 5a, HGA treatment increased RAGE coprecipita-
tion with both Src and PKC.
Western blotting of RAGE immunoprecipitates with anti-
bodies against PKC, PKC, and PKC revealed that these PKC
isoforms did not co-precipitate with RAGE after HGA treat-
ment for 24 h. By contrast, HGA induced the association of
RAGE with PKC (Fig. 5b). Furthermore, RAGE-associated
PKC activity increased in a time-dependent manner after
HGA incubation, reaching a 2-fold increase after 24 h (Fig. 5c).
Thus, uponAGEs treatment RAGEmay form amultimolecular
complex including Src and PKC. Next, cell lysates were pre-
cipitated with RAGE antibodies and tested in overlay assays for
their ability to bind recombinant biotinylated PKC. Two
major bands of 180 and 65 kDa were revealed upon HGA stim-
ulation of the cells, whereas no bands corresponding to the
FIGURE 3. Role of Src in HGA-induced PKC activation in L6 skeletal
muscle cells. a, lysates from L6 skeletalmuscle cells treated or not with 0.1
mg/ml HA or HGA for 24 h in the absence or in the presence of 5 M PP1
were precipitated (IP) with selective anti-PKC antibodies and immuno-
blotted (WB) with anti-phosphotyrosine or anti-PKC antibodies. The
autoradiographs shown are representative of three independent experi-
ments. b, L6 skeletal muscle cells were incubated with 0.1 mg/ml HA or
HGA for 24 h in the absence or in the presence of 5 M PP1. Lipids were
extracted, and determination of DAG levels was performed as described
under “Experimental Procedures.” [32P]Phosphatidic acid was separated
by TLC and quantitated by densitometric analysis. Bars represent the
mean  S.D. of values obtained from three independent experiments in
duplicate. The autoradiographs shown are representative of three inde-
pendent experiments. *, statistically significant differences (**, p  0.01;
***, p  0.001).
FIGURE 4. Role of PLC and PLD in HGA-induced PKC activation in L6
skeletal muscle cells. Cell lysates of L6 skeletal muscle cells incubated with
0.1 mg/ml HA or HGA for 24 h in the absence or in the presence of 0.3%
1-butanol or 10MU73122 (a) or 5MU73343 (b) were then immunoprecipi-
tated with anti-PKC antibody and immunoblotted with antibodies to phos-
pho-PKC or to PKC. The autoradiographs shown are representative of
three independent experiments. *, statistically significant differences (**, p
0.01; ***, p 0.001).
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molecularmass of RAGEwere detected (Fig. 6a). This indicates
that RAGE/PKC is not a direct interaction. Both the apparent
molecular mass andmass spectrometric analysis indicated that
the 180-kDa species corresponded to IRS-1, whereas the
65-kDa was identified as c-Src. Western blot with anti-IRS-1
and anti-PKC antibodies performed on immunoprecipitates
anti-RAGE revealed that HGA treatment increased RAGE co-
precipitation with both IRS-1 and PKC (Fig. 6b).
Role of IRS-1 and Src in PKC and RAGE Association in L6
Skeletal Muscle Cells—To address the functional role of IRS-1
and Src in the activation of PKC induced by HGA, we evalu-
ated the effect of IRS-1 or Src inhibition on RAGE/PKC asso-
ciation. L6 cells were transfected with a specific IRS-1-ri-
bozyme (39), which specifically inhibited IRS-1 expression by
about 80% without affecting PKC levels (Fig. 7a). In untrans-
fected L6 cells, 24 h of HGA treatment induced the association
of RAGE with PKC (Fig. 7b). Interestingly, the transfection of
IRS-1-ribozyme abolishedHGA-induced RAGE/PKC co-pre-
cipitation (Fig. 7b). Furthermore, ribozyme-mediated inhibi-
tion of IRS-1 expression blocked the RAGE-associated PKC
activity induced by HGA (Fig. 7c). The general PKC inhibitor
bisindolyl maleimide was used as a control of PKC activity
(Fig. 7c).
FIGURE 5.HGA-induced association of PKC, Src, and RAGE in L6 skeletal
muscle cells. a, lysates from L6 skeletal muscle cells treated or not with 0.1
mg/ml HA or HGA for 24 h were precipitated (IP) with preimmune serum (PI)
or with selective anti-RAGE antibodies and immunoblotted with anti-PKC,
anti-Src, or anti-RAGE antibodies. The autoradiographs shown are represent-
ative of three independent experiments. b, lysates from L6 skeletal muscle
cells treated as above were precipitated with selective anti-RAGE antibodies
and immunoblotted with PKC, PKC, PKC, or PKC antibodies. The autora-
diographs shown are representative of three independent experiments. c, L6
skeletalmuscle cellswere treatedwith 0.1mg/mlHAorHGA for the indicated
times. Cells were lysed, cell lysates were then precipitatedwith selective anti-
RAGE antibodies, and PKC activity was measured as described under “Exper-
imental Procedures.” Bars represent themean S.D. of values obtained from
three independent experiments in duplicate. *, statistically significant differ-
ences (***, p 0.001).
FIGURE6.HGA induced theassociationof IRS-1withPKCandRAGE inL6
cells. a, L6 skeletal muscle cells were treated with 0.1 mg/ml HA or HGA for
24 h. Cells were lysed as described under “Experimental Procedures,” and
lysates were then precipitated (IP) with selective anti-RAGE antibodies and
loaded on SDS-PAGE. Gels were then transferred onto nitrocellulose filters
and incubated with recombinant biotinylated PKC (OB PKC) as described
under “Experimental Procedures” (left panel). Cell lysates precipitated with
selective anti-RAGE antibodies were also immunoblotted (WB) with PKC
antibody (right panel). The autoradiographs shown are representative of
three independent experiments. b, lysates from L6 skeletal muscle cells
treated as above were precipitated with pre-immune serum (PI) or selective
anti-RAGE antibodies and loaded on SDS-PAGE. Gels were then transferred
onnitrocellulose filters and immunoblottedwith anti-IRS1, anti-PKC, or anti-
RAGE antibodies. The autoradiographs shown are representative of three
independent experiments.
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These results suggest a key role of IRS-1 inmediating RAGE/
PKC interaction. Moreover, inhibition of Src activity by PP1
or the SrcDN prevented the stimulatory effect of HGA on
RAGE-associated PKC activity (Fig. 7d).
Effect of DietaryAGEs onBodyWeight, Food Intake, and Fast-
ing Blood Metabolite Levels—C57/BL6 mice were fed either
LAD or HAD. As assessed by detection of CML-like immuno-
epitopes, AGE content was about 3-fold higher in HAD com-
paredwith LAD (data not shown). Because the daily food intake
was equal between HAD- and LAD-fed mice (Table 3), HAD-
fed mice ingested3-fold more CML than the LAD-fed mice.
This was reflected in part in the fast-
ing serum CML-adducts levels,
which were 2-fold higher in HAD-
fed animals than in LAD-fed ani-
mals (LAD-fed mice 68  8
units/ml versus HAD-fed mice
131 6 units/ml; n 8/group, p
0.02). Thus, steady-state serum lev-
els of AGEswere consistentwith the
estimated content in the dietary for-
mulas. Mice from either diet group
showed no significant differences in
body weight measured during the
entire period of diet (Table 3).
Within 11 weeks of treatment, fast-
ing glucose levels in HAD-fed mice
were significantly increased by 1.3-
fold as compared with LAD-fed
mice and became 1.5-fold higher up
to 22 weeks of diet. At week 22,
HAD-fed mice also featured a 1.4-
fold increase in fasting insulin levels
compared with LAD-fed animals
(Table 3). Similarly, fasting non-
esterified free fatty acid and trig-
lyceride blood concentrations in
HAD-fed mice were increased by
1.25- and 1.60-fold, respectively,
suggesting the presence of insulin
resistance in these animals (Table
3). Interestingly, fasting non-esteri-
fied free fatty acid and triglycerides
in mice were also increased by 1.3-
fold after 9weeks ofHADdespite no
significant differences in fasting glu-
cose levels (Table 3).
Glucose Tolerance and Insulin
Sensitivity in HAD- and LAD-fed
Mice—We then investigated the
effect of HAD on glucose tolerance
by intraperitoneal glucose loading
(2 mg/kg) at week 22. In HAD-fed
mice, blood glucose levels remained
significantly higher than in LAD-fed
mice (area under the curve, 7680
3200 in HAD-fed mice versus
4791  1770 in LAD-fed mice, p 
0.05). To determine possible alterations in insulin sensitivity,
we performed insulin tolerance tests. In LAD-fed mice, intrap-
eritoneal injection of insulin (0.75 milliunits/g of body weight)
caused a severe decrease in blood glucose levels. This decrease
achieved a maximum (70%; p  0.005) after 45 min and was
maintained for further 75 min. At variance, insulin reduced
glucose levels by only 50% after 45 min in HAD-fed mice fol-
lowed by a progressive rescue of the initial blood glucose con-
centration over the following 75 min (area under the curve,
9848 3000 in HAD-fed mice versus 5267 1700 in LAD-fed
mice, p  0.0001) (Fig. 8a). Insulin sensitivity was already
FIGURE 7. IRS-1 and Src are necessary for HGA-induced association of PKC andRAGE in L6 cells. a, L6
skeletal muscle cells were transfected with a specific IRS-1-ribozyme (IRS1-rib) or a control ribozyme (c-rib)
as described under “Experimental Procedures.” Cells were then treated or not with 0.1 mg/ml HA or HGA
for 24 h. Cells were lysed as described under “Experimental Procedures,” and lysates were then immuno-
blotted with IRS1 or PKC antibodies. The autoradiographs shown are representative of three independ-
ent experiments. b, lysates from L6 skeletal muscle cells treated as above were precipitated (IP) with
selective RAGE antibodies and loaded on SDS-PAGE. Gels were then transferred on nitrocellulose filters
and immunoblotted with PKC or RAGE antibodies. The autoradiographs shown are representative of
three independent experiments. c, L6 skeletal muscle cells were transfectedwith a specific IRS-1-ribozyme
(IRS-1-rib) or a control ribozyme (c-rib) as described under “Experimental Procedures” then treated or not
with 0.1 mg/ml HA or HGA for 24 h in the absence or presence of 100 nM bisindolyl maleimide. Cells were
lysed, cell lysates were then precipitated with selective anti-RAGE antibodies, and PKC activity was meas-
ured as described under “Experimental Procedures”. d, L6 skeletal muscle cells were incubated with 0.1
mg/ml HA or HGA for 24 h in the absence or in the presence of 5 M PP1. Alternatively, L6 skeletal muscle
cells were also mock-transfected or transfected with a kinase-inactive dominant negative Src (SrcDN), as
described under “Experimental Procedures” and then incubated with 0.1 mg/ml HA or HGA for 24 h. Cells
were lysed, cell lysates were then precipitated with selective anti-RAGE antibodies, and PKC activity was
measured as described under “Experimental Procedures.” Bars represent the mean  S.D. of three inde-
pendent experiments. *, statistically significant differences (**, p  0.01, ***, p  0.001).
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reduced inmice after 9 weeks of HAD, as shown in Fig. 8b (area
under the curve, 8522 2419 in HAD-fed mice versus 5920
1215 in LAD-fed mice, p 0.01).
Effect of HAD on Glucose Uptake, PKB/Akt, and PKC Acti-
vation in Vivo—In cultured L6 skeletal muscle cells, incubation
withHGA causes resistance to insulin action on glucose uptake
(31). We, therefore, tested whether HAD also impairs insulin
stimulation of the glucose transport machinery in vivo. Insulin-
stimulated glucose uptake in the quadriceps and tibialis mus-
cles from 22-week HAD-fed animals was decreased by 42 and
56%, respectively, compared with the LAD-fed mice (Fig. 8, c
and d). Insulin-stimulated glucose uptake was reduced also in
the quadriceps from 9-week HAD-fedmice (Fig. 8c). In parallel
with the decreased glucose uptake, phosphorylation of PKB/
Akt in response to insulinwas also significantly reduced in skel-
etal muscles from HAD-fed mice (Fig. 9, a and b). This abnor-
mality was accompanied by no significant change in the total
PKB/Akt levels.Wehave previously demonstrated that the neg-
ative effects of HGA on insulin metabolic signaling in L6 myo-
tubes are specifically mediated by PKC (31). We, therefore,
measured PKC-specific activity in muscles from both HAD-
and LAD-fed mice. As shown in Fig. 9c, PKC specific activity
measured in fasting conditions was increased by 2.3- and 1.8-
fold in muscles from 22- and 9-week HAD-fed mice, respec-
tively, compared with LAD-fed mice. Thus, AGEs modulate
insulin signaling and PKC activity in vivo as well as in cultured
cells.
HAD-induced Src Activation and Association of PKC, Src,
and RAGE inMice Skeletal Muscles—To investigate the abil-
ity of HAD to activate Src and to induce the formation of the
complex between Src, RAGE, and/or PKC in vivo, muscle
tissue lysates fromHAD- or LAD-fed mice were blotted with
anti-phospho-Src Tyr416 antibody. An 2-fold increase of
Src phosphorylation was observed in tibialis muscle from
both 9- and 22-week HAD-fed mice compared with LAD-fed
mice (Fig. 10). Furthermore, as shown in Fig. 11, RAGE
coprecipitation with both Src and PKC was increased in
lysates from muscles from C57/BL6 HAD-fed mice when
compared with LAD-fed mice. An increase of RAGE-associ-
ated PKC activity was also observed in HAD fed mice (data
not shown).
Glycated Albumin-induced PKC and Src Activation inMice
Skeletal Muscles—To further support the role of AGEs in the
activation of both PKC and Src in vivo, C57/BL6 mice were
injected with HGA either directly in the skeletal muscle (GA-
Im) or in the tail vein (GA-Iv) as described under “Experimental
Procedures.” Muscle tissue lysates from GA-Im and GA-Iv
mice were blotted with either anti-phospho PKC (Fig. 12, a, c,
e, and g) or Src Tyr416 antibody (Fig. 12, b, d, f, and h). An
2-fold increase of both PKC (Fig. 12, a and c) and Src phos-
phorylation (Fig. 12, b and d) was observed in quadriceps from
GA-Im mice compared with mice treated with vehicle alone
FIGURE 8. Insulin sensitivity and glucose transport in LAD- and HAD-
fed mice. a, 4-week-old female mice of the C57/BL6 strain were fed a LAD
or a HAD diet as described under “Experimental Procedures.” At week (w)
22 (a) and week 9 (b) mice were injected intraperitoneally with insulin
(0.75 milliunits/g of body weight) followed by determinations of blood
glucose levels at the indicated times. Values are expressed as themeans
S.D. c and d, mice fed LAD or HAD for 9 or 22 weeks were subjected to
intravenous injection of 1 Ci of 2-deoxy-D-[1-3H]glucose and intraperito-
neal injection of insulin. Quadriceps (c) or tibialis (d) muscles were
removed 30 min after and snap-frozen in liquid nitrogen. 2-Deoxy-D-[1-
3H]glucose accumulated in muscle tissues was quantitated as described
under “Experimental Procedures.” Bars represent mean values  S.D. of
determinations in at least seven mice/group. *, statistically significant dif-
ferences (*, p  0.05; **, p  0.01; ***, p  0.001).
TABLE 3
Mice were analyzed as described under “Experimental Procedures.” Data are the the means S.D. of determinations in
12 LAD- and 12 HAD-fed mice
LAD HAD
Base line Week 9 Week 11 Week 22 Base line Week 9 Week 11 Week 22
Food intake (g/day) 3.30 0.10 3.46 0.20 3.44 0.14 4.30 0.24 3.50 0.22 3.88 0.15 3.58 0.15 4.04 0.20
Weight (g) 14.3 2.2 20.4 1.0 20.8 1.6 23.1 1.7 14.4 1.8 20.4 0.9 20.5 1.6 22.2 0.8
Fasting blood glucose (mg/dl) 69 13 69 22 79 16 80 12 68 10 78 12 103 15a 117 12b
Fasting serum insulin (mmol/liter) ND ND ND 4.99 1.18 ND ND ND 7.48 2.70a
Fasting NEFA (mmol/liter) ND 0.35 0.07 ND 0.43 0.08 ND 0.45 0.02c ND 0.53 0.09c
Fasting triglycerides (mg/ml) ND 0.49 0.02 ND 0.59 0.12 ND 0.64 0.07c ND 0.95 0.27c
a p 0.01.
b p 0.001.
c p 0.05.
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(PBS) or with non-glycated albumin (HA). Furthermore, both
PKC (Fig. 12, e and g) and Src phosphorylation (Fig. 12, f andh)
were increased by 2.5- and 1.8-fold, respectively, in muscle
lysates from GA-Iv mice when compared with PBS or
HA-treated mice.
DISCUSSION
We have previously shown that in L6 skeletal muscle cells
chronic exposure toHGA selectively inhibits the phosphatidyl-
FIGURE 9. Effect of LAD and HAD on PKB/Akt and PKC activation in vivo.
a, 4-week-old femalemice of the C57/BL6 strainwere fed a LADor aHADdiet as
described under “Experimental Procedures.” At week (w) 22 (a) and week 9 (b),
mice were injected intraperitoneally with insulin (0.125 milliunits/g of body
weight), and muscle tissues were collected and homogenized. Tissue homoge-
nateswere subjected toSDS-PAGE followedby immunoblottingwithantibodies
tophosphoserine 473PKB/Akt and toPKB/Akt as a control. PKB/Akt phosphoryl-
ation was analyzed by densitometry. Bars represent the mean  S.D. of three
different experiments. c, at week 9 or at week 22 muscle tissues homogenates
weresubjectedtoimmunoprecipitationwithPKCantibodies,andspecificPKC
activity was measured as described under “Experimental Procedures.” Bars rep-
resent themean S.D. of three independent experiments. *, statistically signifi-
cant differences (**, p 0.01; ***, p 0.001).
FIGURE 10. Effect of LAD andHAD on Src activation in vivo. a, tibialis mus-
cle homogenates from22weeks (w) LAD- orHAD-fedmicewere separatedby
SDS-PAGE followed by immunoblotting with antibodies to phosphotyrosine
416 Src or total Src. The autoradiographs shown are representative of three
independent experiments. b, densitometric analysis of phosphotyrosine 416
Src normalized on total Src. c, tibialismuscle homogenates from9-week LAD-
or HAD-fed mice were separated by SDS-PAGE followed by immunoblotting
with antibodies to phosphotyrosine 416 Src or total Src. The autoradiographs
shown are representative of three independent experiments. d, densitomet-
ric analysis of phosphotyrosine 416 Src normalized on total Src. *, statistically
significant differences (*, p 0.05).
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inositol 3-kinase/PKB pathway in the insulin signaling cascade
while leaving the Ras-ERK activation and mitogenic action of
the hormone unaltered (31). In L6myotubes the HGA-induced
alteration of insulin metabolic signals is paralleled by an
increase of serine/threonine phosphorylation of the IRSs spe-
cifically mediated by the activation of PKC independently of
reactive oxygen species (31). Previous studies have shown that
the PKC family of serine/threonine kinases is implicated in
development of insulin resistance (40, 41). The PKC family is
composed of several isoforms, divided into three groups
according to their structure and activation mechanisms (42).
The atypical isoforms play a positive role in glucose transport
(43), whereas classical isoforms are involved in generation of
insulin resistance. It is well established that PKC and - are
able to phosphorylate insulin receptor and IRSs on serine and
threonine residues, inhibiting their tyrosine phosphorylation
(44–46).
Importantly, our studies revealed that in L6 cells inhibition of
Src kinase, either by a specific pharmacological inhibitor such
as PP1 or by transfecting a dominant negative form of the
kinase, prevents the HGA-induced increase in PKC activity,
suggesting a key role for Src in this event. Interestingly, PKC is
tyrosine-phosphorylated uponHGA treatment, and its tyrosine
phosphorylation is abolished by preincubation of L6 cells with
PP1. Thus, Src may directly regulate PKC activity in response
to HGA. Furthermore, these effects appear to be RAGE-medi-
ated as a soluble form of RAGE was able to prevent both HGA-
induced Src and PKC activation. PKC activity is implicated in
v-Src-induced intracellular signals. In the rat large intestine
1,25-dihydroxyvitamin stimulates the physical association of
activated c-Src with PLC and activates two Ca2-dependent
PKC isoforms (47). Similarly, activation of v-Src in BALB/c 3T3
cells rapidly increases the intracellular secondmessenger, DAG
via a typeDphospholipase/PAphosphatase-mediated signaling
pathway (48). These results are consistent with our findings
that HGA caused a Src-dependent increase in the amount of
DAG in L6 skeletal muscle cells. Moreover, we show that treat-
ment of L6 cells with the pharmacological inhibitor of PLC,
U73122, but not its inactive structural analogueU73343, almost
completely abolishes HGA-induced PKC phosphorylation,
indicating that, in response to HGA, Src may increase the
amount of DAG via PLC. Thus, Src may control PKC activity
by direct phosphorylation and by regulation of DAG intracel-
lular levels via PLC.
HGA-induced increase in DAG levels is not sufficient to
activate other PKC isoforms, as we have already described
(31). Previous work by Zang et al. (49) demonstrated that in
cells expressing the oncogenic v-Src, increased production
of DAG is accompanied by a selective activation of the  and
 isoforms of PKC, whereas the  isoform is not activated.
Furthermore, Pula et al. (50) have shown that in platelets
PKC but not PKC was activated in an Syk- and phospho-
lipase C-dependent manner. It has been proposed that spe-
cific DAG species are generated to activate specific PKC iso-
forms. Indeed, several reports have demonstrated that
different stimuli generate different DAG species, and PKC
isotypes are differentially sensitive to the fatty acid compo-
sition of DAG (51). Thus, it is possible that in L6 cells the lack
of activation of other PKC isoforms is due to specific DAG
produced by HGA stimulation.
We then hypothesized that HGA could activate Src via
RAGE. Reddy et al. (30) showed that S100B activates Src
kinase in a RAGE-dependent manner and that Src kinase is
required for the S100B-induced RAGE signaling, leading to
migration and inflammatory gene expression in vascular
smooth muscle cells. Co-localization of RAGE and Src has
been evidenced in caveolae (30), where Cav-1 plays an
important role in the assembly and integration of signaling
complexes (52, 53). It is well known that RAGE can activate
several downstream signaling pathways, including ERK1/2,
phosphatidylinositol 3-kinase, PKC, the Janus tyrosine
kinases (JAKs), and transcription factors, including STAT3,
AP1, and NF-B (22, 26). Moreover, the cytoplasmic region
of RAGE is responsible for the binding of the signaling mol-
ecule(s). In intact cells, ERK1/2 have been identified as
RAGE-binding proteins. Binding to the intracellular region
of RAGE localizes ERK under the proximal region of the
plasma membrane, enabling the interaction between ERK
and its substrates (27). Our results are consistent with the
hypothesis that the formation of a multimolecular complex,
involving RAGE, PKC, and Src kinase, occurs in response to
chronic HGA treatment. Indeed, coprecipitation experi-
ments showed that in L6 cells Src kinase interacts with both
RAGE and PKC. RAGE cytoplasmic domain might also be
involved in the interaction of RAGE with both Src and
PKC. Fine mapping of the interaction sites between Src,
PKC, and RAGE is currently under investigation in our
laboratory.
FIGURE 11. Effect of LAD and HAD on PKC, Src, and RAGE association in
vivo. Tibialis muscle homogenates from mice fed LAD or HAD for 22 weeks
(w) (a) or for 9 weeks (b) were precipitated (IP) with preimmune serum (PI) or
with selective anti-RAGE antibodies and immunoblotted with anti-PKC,
anti-Src or anti-RAGE antibodies. The autoradiographs shown are represent-
ative of four independent experiments.
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Overlay blot assays revealed that, in response to HGA, a 180-
kDa protein, identified as IRS-1, and Src may directly bind
PKC. Thus, HGAmay induce direct interaction of PKCwith
IRS1 and Src. IRS1, or less likely Src, in turn may bridge RAGE
interaction with PKC, the latter two having no direct interac-
tion. Indeed, our experiments in L6 cells transfected with IRS-1
ribozyme indicate that IRS-1 is required for RAGE-PKC co-
precipitation and activation in response to HGA. This is con-
sistent with our previous findings showing that IRS-1 but not
IRS-2 expression is necessary to allow classical PKC activation
in response to insulin (39). Thus,
one might speculate that, in
response to different stimuli, PKC
is involved in the formation of dif-
ferent specific multimolecular com-
plexes, which modulate insulin sen-
sitivity. In this paperwe also provide
evidence that dietary AGEs are able
to affect insulin sensitivity and glu-
cose tolerance in vivo. These effects
were AGEs-specific and not caused
by hyperglycemia, as C57/BL6 mice
fed a HAD for 9 weeks show a
reduction of insulin sensitivity
despite no significant differences in
fasting glucose levels (Table 3). Pro-
longed exposure to HAD subse-
quently led to higher fasting glucose
levels after 11weeks of diet up to the
end of the treatment comparedwith
mice fed a LAD despite equal food
intake and weight gain. Throughout
this period HAD-fed mice appear
consistently hyperinsulinemic in
fasting conditions and exhibit
increased non-esterified free fatty
acid and triglycerides levels com-
pared with LAD-fed mice. Because
glucose tolerance is also slightly
impaired at 22 weeks of HAD, it is
conceivable that dietaryAGEs affect
insulin secretion in addition to
insulin action. This is consistent
with the evidence that accumula-
tion of islet AGEs could be impor-
tant for glucotoxicity toward -cells
(54). Furthermore, insulin-induced
PKB phosphorylation and glucose
uptake are dramatically reduced in
tibialis and quadriceps muscles of
HAD-fedmice. Impairment of insu-
lin metabolic signaling is accompa-
nied by an increase in PKC specific
activity in tibialis muscles from the
HAD-fed mice, showing again that
the mechanism by which HGA
exacerbates the insulin-resistant
state in intact cells also occurs in
vivo. Moreover, an increase in PKC specific activity in tibialis
muscles from the HAD-fed mice appeared to be associated to
the increase of the RAGE-PKC-Src complex formation.
Increases of both PKC and Src phosphorylation were also
observed when HGA was delivered either by direct intramus-
cular or by intravenous injection in mice. These observations
further support the in vivo relevance of HGA and the conclu-
sion that the differences in LAD- andHAD-fedmice are largely
due to AGEs. In summary, our data suggest that AGEs-induced
PKC activity in the muscle might be mediated by the forma-
FIGURE 12. Effect of glycated albumin on PKC and Src activation in vivo. 4-Week-old female mice of the
C57/BL6 strain were injected with 50mg/kg of HGA or HA or PBS either directly in the quadriceps (GA-Im: a, b,
c, and d) or in the tail vein (GA-Iv: e, f, g, and h) as described under “Experimental Procedures. a and c, muscle
tissue lysates from muscle-injected mice were blotted with anti-phospho PKC, and PKC phosphorylation
was analyzed by densitometry. b and d, muscle tissue lysates from muscle-injected mice were blotted with
anti-phospho Src Tyr416 antibody and Src phosphorylation was analyzed by densitometry. e and g, muscle
tissue lysates from tail vein-injected mice were blotted with anti-phospho PKC, and PKC phosphorylation
was analyzed by densitometry. f and h, muscle tissue lysates from tail vein-injected mice were blotted with
anti-phospho-Src Tyr416 antibody, and Src phosphorylation was analyzed by densitometry. A representative
autoradiograph is shown. Bars represent the mean S.D. of three different experiments. *, statistically signif-
icant differences (*, p 0.05).
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tion of a RAGE-PKC-Src-IRS1 complex both in vitro and
in vivo.
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Abstract
Aims/hypothesis Glucosamine, generated during hypergly-
caemia, causes insulin resistance in different cells. Here we
sought to evaluate the possible role of endoplasmic
reticulum (ER) stress in the induction of insulin resistance
by glucosamine in skeletal muscle cells.
Methods Real-time RT-PCR analysis, 2-deoxy-D-glucose
(2-DG) uptake and western blot analysis were carried out
in rat and human muscle cell lines.
Results In both rat and human myotubes, glucosamine
treatment caused a significant increase in the expression of
the ER stress markers immunoglobulin heavy chain-binding
protein/glucose-regulated protein 78 kDa (BIP/GRP78 [also
known as HSPA5]), X-box binding protein-1 (XBP1) and
activating transcription factor 6 (ATF6). In addition,
glucosamine impaired insulin-stimulated 2-DG uptake in
both rat and human myotubes. Interestingly, pretreatment of
both rat and human myotubes with the chemical chaperones
4-phenylbutyric acid (PBA) or tauroursodeoxycholic acid
(TUDCA), completely prevented the effect of glucosamine
on both ER stress induction and insulin-induced glucose
uptake. In both rat and human myotubes, glucosamine
treatment reduced mRNA and protein levels of the gene
encoding GLUT4 and mRNA levels of the main regulators
of the gene encoding GLUT4 (myocyte enhancer factor 2 a
[MEF2A] and peroxisome proliferator-activated receptor-γ
coactivator 1α [PGC1α]). Again, PBA or TUDCA pre-
treatment prevented glucosamine-induced inhibition of
GLUT4 (also known as SLC2A4), MEF2A and PGC1α
(also known as PPARGC1A). Finally, we showed that
overproduction of ATF6 is sufficient to inhibit the
expression of genes GLUT4, MEF2A and PGC1α and that
ATF6 silencing with a specific small interfering RNA is
sufficient to completely prevent glucosamine-induced inhi-
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bition of GLUT4, MEF2A and PGC1α in skeletal muscle
cells.
Conclusions/interpretation In this work we show that
glucosamine-induced ER stress causes insulin resistance in
both human and rat myotubes and impairs GLUT4
production and insulin-induced glucose uptake via an
ATF6-dependent decrease of the GLUT4 regulators MEF2A
and PGC1α.
Keywords ER stress . Glucosamine . Insulin resistance .
Skeletal muscle
Abbreviations
2-DG 2-Deoxy-D-glucose
ATF6 Activating transcription factor 6
BIP/GRP78 Immunoglobulin heavy chain-binding
protein/glucose-regulated protein 78 kDa
ChIP Chromatin immunoprecipitation assay
eIF2α Eukaryotic translation initiation factor 2α
ER Endoplasmic reticulum
GEF GLUT4 enhancer factor
GlcN Glucosamine
GFAT Glutamine:fructose-6-phosphate
amidotransferase
HBP Hexosamine biosynthetic pathway
HG High glucose
MEF2A Myocyte enhancer factor 2 a
MnTBAP Mn(III)tetrakis(4-benzoic acid)
porphyrin chloride
NAC N-Acetyl-cysteine
PBA 4-Phenylbutyric acid
PERK Double-stranded RNA-activated
protein kinase-like ER kinase
PGC1α Peroxisome proliferator-activated
receptor-γ coactivator 1 α
PUGNAc O-(2-Acetamido-2-deoxy-D-glucopy-
ranosylidenamino)N-phenylcarbamate
SHP Orphan nuclear receptor small
heterodimer partner
siRNA Small interfering RNA
Thap Thapsigargin
TUDCA Tauroursodeoxycholic acid
UPR Unfolded protein response
XBP-1s X-box binding protein-1, spliced active
form
XBP-1t X-box binding protein-1, total form
Introduction
The endoplasmic reticulum (ER) is the principal site of
protein synthesis, and together with the Golgi apparatus it
facilitates transport and release of correctly folded proteins.
Under conditions of cellular stress leading to an impairment
of ER function, proteins are unable to fold properly and
accumulate in the ER lumen. It is because of these unfolded
or misfolded proteins that the ER has evolved a coping
system known as the unfolded protein response (UPR) [1, 2].
Cellular stresses that may elicit UPR activation in-
clude glucose and energy deprivation, increased protein
synthesis, inhibition of protein glycosylation and imbal-
ance of ER calcium levels [3, 4]. In mammalian cells, at
least four functionally distinct responses have been
identified and three ER-resident transmembrane proteins
have been described as primary sensors and transducers of
the UPR: the double-stranded RNA-activated protein
kinase-like ER kinase (PERK), inositol requiring-1, and
activating transcription factor 6 (ATF6) [5–7]. The first
response, mediated by PERK, is translational attenuation,
to reduce the load of new protein synthesis and prevent
further accumulation of unfolded proteins [8]. The second
response is upregulation of genes encoding ER chaperone
proteins such as the immunoglobulin heavy chain-binding
protein/glucose-regulated protein 78 kDa (BIP/GRP78)
and the glucose-regulated protein 94 kDa, to increase the
ER protein-folding capacity [7, 9]. The third response is
transcriptional activation of genes involved in the degra-
dation of misfolded protein in the ER by the ubiquitin–
proteasome system, called ER-associated degradation
[10]. The fourth response is apoptosis, which occurs when
severe and prolonged ER stress impairs ER functions, to
protect the organism by eliminating the damaged cells [4].
ER stress plays an important role in several human
diseases, including type 2 diabetes; indeed, recent studies
reported that ER stress is involved in both pancreatic beta
cell dysfunction [11–13] and peripheral insulin resistance
[14, 15].
While the consequences of ER stress have been widely
studied in adipose tissue and liver, ER stress in skeletal
muscle, the major site of glucose disposal, has not received
equal attention. The hexosamine biosynthetic pathway
(HBP) is a minor glucose metabolic pathway that metabolises
∼3% of glucose entering the cell, and the final product of this
pathway, UDP-N-acetylglucosamine, as other nucleotide
hexosamines, is used in the ER as substrate for protein
glycosylation [16, 17]. Although quantitatively using a
small fraction of glucose, HBP is an important contributor
to the insulin-resistant state. Several studies have shown,
indeed, that chronic exposure to glucosamine (GlcN), a
precursor of the HBP, impairs insulin responsiveness, thus
contributing to the formation of an insulin-resistant state in
cultured human skeletal muscle cells and rat adipocytes [17]
as well as in vivo [18]. However, the precise mechanisms by
which GlcN induces insulin resistance have not been
conclusively established in these studies.
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Methods
Materials DMEM, FBS, FCS, L-glutamine and BSA were
from Invitrogen (Paisley, UK). Thapsigargin (Thap), GlcN,
4-phenylbutyric acid (PBA) and N-acetyl-cysteine (NAC),
were from Sigma-Aldrich (St Louis, MO, USA). Mn(III)
tetrakis(4-benzoic acid) porphyrin chloride (MnTBAP) and
tauroursodeoxycholic acid (TUDCA) were from Calbio-
chem (San Diego, CA, USA). Other reagents were as
follows: Ultroser G (Pall Biosepra, Cergy, France), 2-
deoxy-D-[14C]glucose (2-DG) (Perkin Elmer, Waltham,
MA, USA), insulin (Novo Nordisk, Bagsværd, Denmark),
GLUT4 (Abcam, Cambridge, UK), myocyte enhancer
factor 2 a (MEF2A), peroxisome proliferator-activated
receptor-γ coactivator 1α (PGC1α), eukaryotic translation
initiation factor 2α (eIF2α) and phospho-eIF2α antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), small
interfering RNA (siRNA) and siPORT NeoFX Transfection
Agent (Applied Biosystems, Carlsbad, CA, USA)
Cell culture procedures and 2-DG uptake Human cell
cultures from lean individuals were established as described
previously [19–21] (Table 1). Cells were cultured in
DMEM supplemented with 2% (vol./vol.) FCS, 2% (vol./
vol.) Ultroser G and antibiotics. Human myotubes were
allowed to differentiate under physiological conditions of
insulin (25 pmol/l) and glucose (5.5 mmol/l) for 4 days. L6
rat skeletal muscle myoblasts were grown in DMEM
supplemented with 10% (vol./vol.) FBS, 2 mmol/l L-
glutamine and antibiotics. L6 myotubes were allowed to
differentiate as described previously [22]. 2-DG uptake was
measured as reported previously [23].
Real-time RT-PCR and western blot analysis Total RNA
extraction, cDNA synthesis and real-time RT-PCR analysis
were performed as described previously [24]. Primer sequen-
ces are in Electronic supplementary material (ESM) Table 1.
Cell lysates and immunoblotting were carried out as described
previously [22]. Antibodies against GLUT4, phospho-eIF2α
and eIF2α were used for detection of proteins.
Chromatin immunoprecipitation (ChIP) assay ChIP assays
were performed as reported [25]. Vehicle- or reagent-treated
myotubes were fixed with 1% (vol./vol.) formaldehyde at
37°C. The fixed cells were lysed in a SDS lysis buffer (1%
[wt/vol.] SDS, 10 mmol/l EDTA and 50 mmol/l TRIS–HCl,
pH 8.1), incubated on ice, and sonicated to shear DNA.
Sheared chromatin samples were taken as input control or
used for immunoprecipitation with anti-MEF2A, anti-
PGC1α or non-immune antibodies. DNA fragments were
recovered and were subjected to real-time RT-PCR ampli-
fication by using specific primers for the analysed regions.
Atf6 siRNA-mediated knockdown Cells were transfected
with 5 nmol/l of siRNA negative control and Atf6 siRNA
(GCUUGUCAGUCACGAAAGAtt) and antisense
(UCUUUCGUGACUGACAAGCag) according to the
manufacturer’s recommendations and processed 48 h after
transfection.
Statistical procedures Data were analysed with Statview
software (Abacus Concepts, Piscataway, NJ, USA) by one-
factor analysis of variance. p<0.05 was considered statis-
tically significant.
Results
To investigate the role of GlcN in ER stress induction,
differentiated L6 skeletal muscle cells were treated with
different concentrations of GlcN. The classic ER stress
inducer Thap, an inhibitor of sarcoplasmic/ER calcium-
transporting ATPases, was used as a control of ER stress
induction [2]. In L6 myotubes, Thap induced a 17-fold
increase of the chaperone Bip/grp78 (also known as Hspa5)
mRNA (Fig. 1a), indicating that our cellular model was
sensitive to ER stress. Bip/grp78 mRNA levels were
increased also by GlcN, with a maximal expression
observed at 10 mmol/l GlcN for 24 h (Fig. 1b). Interest-
ingly, pretreatment of cells with azaserine, a non-specific
but commonly used inhibitor of the glutamine:fructose-6-
phosphate amidotransferase (GFAT) [26, 27], the rate-
limiting enzyme of the HBP, prevented high glucose
(HG)-induced ER stress (ESM Fig. 1a). In addition,
treatment of cells with the peptide O-acetylglucosamine-
β-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-de-
oxy-D-glucopyranosylidenamino)N-phenylcarbamate
(PUGNAc), did not increase Bip/grp78 mRNA levels,
suggesting that enhanced O-linked glycosylation was not
Table 1 Biochemical features of the euglycaemic individuals (n=5)
Variable Value
Age (years) 55.3±2.2
BMI (kg/m2) 23.0±1.1
Fasting plasma glucose (mmol/l) 5.4±0.2
Fasting plasma insulin (pmol/l) 35.2±7.8
HbA1c (%) 5.6±0.1
Values represent means ± SD
Muscle biopsies were obtained from the vastus lateralis muscle of five
lean individuals by needle biopsy under local anaesthesia [19].
Subjects had normal glucose tolerance and no family history of
diabetes. Individuals gave written, informed consent, and the local
ethics committee of Funen and Vejle county (Denmark) approved the
study
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responsible for the induction of ER stress (ESM Fig. 1a).
To evaluate whether GlcN-induced ER stress could be
mediated by oxidative stress, L6 myotubes were pretreated
with two anti-oxidants, the glutathione precursor NAC and
the superoxide dismutase mimetic MnTBAP. Pretreatment
of cells with both NAC and MnTBAP did not affect GlcN-
induced Bip/grp78 mRNA increase, suggesting that GlcN-
induced ER stress was not dependent on oxidative stress in
skeletal muscle cells (Fig. 1b). Then we evaluated the
effects of different concentrations of GlcN on ATP
intracellular levels. GlcN depleted the ATP pool only at
the highest concentrations, suggesting that GlcN-induced
ER stress was not dependent on ATP depletion in skeletal
muscle cells (ESM Fig. 2). As expected, xylose did not
induce a Bip/grp78 mRNA increase, even at high concen-
trations (Fig. 1b), thus excluding an osmotic stress effect
caused by treatments. Time course analysis with 7.5 mmol/
l GlcN showed that Bip/grp78 expression was significantly
increased as early as 2 h after the treatment and was
elevated up to 16 h (Fig. 1c). To investigate whether chemical
chaperones could prevent GlcN-induced ER stress, we
analysed Bip/grp78 mRNA in L6 myotubes treated with
GlcN in the presence of either 10 mmol/l PBA, a low
molecular weight non-specific chemical chaperone known to
stabilise protein conformation and to improve ER folding
capacity [28], or 5 mmol/l TUDCA, a bile acid derivative that
also modulates ER function [28]. Both PBA and TUDCA
almost completely prevented the effect of GlcN on Bip/grp78
mRNA (Fig. 1d). These data suggest that GlcN is able to
induce ER stress in skeletal muscle cells and that this effect is
prevented by chemical chaperones.
To verify whether GlcN was able to induce UPR
activation, L6 myotubes were treated with GlcN or Thap
and different markers of UPR activation were analysed. The
mRNA levels of the gene (Xbp1) encoding the spliced
active form of the X-box binding protein-1 (XBP-1; Xbp1
s) increased significantly following both Thap (Fig. 2a) and
GlcN treatments (Fig. 2b). Time course experiments
showed that the increase of Xbp1 s peaked at 8 h of GlcN
treatment and remained higher than basal level up to 24 h
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Fig. 1 GlcN induces BIP/GRP78 in L6 myotubes. a–d Bip/grp78
mRNA was determined by real-time RT-PCR analysis of total RNA
isolated from myotubes, using Gapdh as internal standard. mRNA
levels in treated cells are relative expression units (REU) to those in
control (C; mean ± SD; n=8). ***p<0.001. a L6 cells were treated
with 0.5 µmol/l Thap for 30 min, followed by 24 h without Thap.
b L6 cells were pretreated or not with 5 mmol/l NAC or with 1 mg/ml
MnTBAP for 2 h and then cultured in the presence of GlcN or xylose,
as indicated, for 24 h. c Time course of Bip/grp78 mRNA in L6 cells
cultured with 7.5 mmol/l GlcN for the indicated times. d L6 cells were
pretreated or not for 1 h with 10 mmol/l PBA or 5 mmol/l TUDCA
and then treated with 7.5 mmol/l GlcN for 24 h
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(Fig. 2b). In addition, also the mRNA levels of the genes
encoding the total form of XBP-1 (Xbp1 t) and ATF6 (Atf6)
were significantly increased upon both Thap (Fig. 2c,e) and
GlcN treatments (Fig. 2d,f). Furthermore, phosphorylation
of eIF2α was evident as early as 30 min after both GlcN
and Thap treatment, and it persisted up to 24 h following
GlcN treatment (Fig. 2g). These data suggest that GlcN
caused UPR activation in L6 myotubes.
To investigate the effect of GlcN-induced ER stress on
the insulin sensitivity of skeletal muscle cells, insulin-
induced glucose uptake was evaluated in L6 myotubes
treated with GlcN for 24 h. GlcN treatment reduced the
capability of L6 cells to take up the glucose analogue 2-DG
upon insulin stimulation, compared with control cells
(Fig. 3a). Similar results were obtained when cells were
treated with Thap (data not shown) and HG (ESM Fig. 1b).
To verify the hypothesis that GlcN and HG may impair
glucose uptake in L6 cells through ER stress induction, we
analysed insulin-induced glucose uptake in cells treated
with either GlcN or HG in the presence of PBA or TUDCA.
Interestingly, both PBA and TUDCA prevented GlcN
(Fig. 3a) and HG (ESM Fig. 1b) effects on insulin-
stimulated glucose uptake, suggesting that ER stress caused
insulin resistance in skeletal muscle cells.
We then evaluated GlcN effects on the expression of
GLUT4, since it is the main glucose transporter responsible
for insulin-mediated glucose uptake in muscle [29]. Time
course analysis showed that Glut4 (also known as Slc2a4)
mRNA levels were significantly decreased as early as 6 h
after GlcN treatment, and were reduced by about 50% after
16 h of treatment (Fig. 3b). Glut4 mRNA levels did not show
any significant variation when L6 myotubes were treated
with GlcN in the presence of PBA (Fig. 3c). In addition, the
GlcN-dependent decrease of Glut4 mRNA expression was
paralleled by a similar reduction of GLUT4 protein levels
and this was also prevented by pretreatment with PBA
(Fig. 3d). As for GlcN, both Thap (data not shown) and HG
treatment (ESM Fig. 1c), induced a significant decrease of
both GLUT4 protein and mRNA levels compared with
control cells. These data indicated that GlcN and HG reduced
Glut4 expression through the induction of ER stress.
Actinomycin D treatment did not further decrease Glut4
mRNA upon GlcN treatment, suggesting that GlcN-induced
ER stress determined a transcriptional inhibition of Glut4 in
skeletal muscle cells, without affecting its mRNA stability
(data not shown). To gain further insight into the mecha-
nisms leading to Glut4 reduced transcription, we analysed
the expression of genes relevant to Glut4 transcriptional
regulation by real-time RT-PCR analysis. Time course
experiments showed that GlcN caused a significant reduc-
tion of Mef2a mRNA expression as early as 6 h after the
treatment, with a 60% reduction at 16 h (Fig. 4a). Similarly,
MEF2A coactivator Pgc1α (also known as Ppargc1a) was
reduced by 50% after 16 h of treatment compared with
control cells (Fig. 4c). As for GlcN, both Thap (data not
shown) and HG treatment (ESM Fig. 1c) induced a
significant decrease of Mef2a and Pgc1α expression levels.
L6 cells treated with GlcN in the presence of PBA
exhibited no differences in the mRNA levels of both Mef2a
(Fig. 4b) and Pgc1α (Fig. 4d) compared with control cells,
confirming that also Mef2a and Pgc1α reduced expression
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Fig. 2 GlcN induces UPR activation in L6 myotubes. a–g L6 cells
were treated with 0.5 µmol/l Thap for 30 min, followed by 24 h
without Thap, or with 7.5 mmol/l GlcN for the indicated times (a–f).
Xbp1 s (a, b), Xbp1 t (c, d) and Atf6 (e, f) mRNAs in treated cells are
relative expression units (REU) to those in control (C; mean ± SD; n=
7) and were determined by real-time RT-PCR analysis, using Gapdh
as internal standard. *p<0.05; ***p<0.001. g L6 cells treated with
0.5 µmol/l Thap for 30 min, followed by 24 h without Thap (left), or
with 7.5 mmol/l GlcN (right) for the indicated times, were solubilised
and equal amounts of proteins (80 µg per sample) were analysed by
western blotting using phospho-eIF2α Ser51 and eIF2α specific
antibodies (n=5)
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was dependent on GlcN-induced ER stress. To establish
whether the reduction of Mef2a and Pgc1α expression
induced by ER stress was paralleled by a reduced binding
of these two proteins to the GLUT4 promoter, we
performed ChIP and re-ChIP experiments in L6 cells
treated with GlcN. MEF2A binding to GLUT4 promoter
showed a 60% decrease upon GlcN treatment compared
with control cells (Fig. 4e). Similarly, PGC1α indirect
binding to GLUT4 promoter measured by re-ChIP assay
was reduced by 40% upon GlcN treatment compared with
control cells (Fig. 4f). These data indicate that GlcN-
induced ER stress causes the transcriptional inhibition of
Glut4, at least in part by reducing both Mef2a and Pgc1α
mRNA levels and their binding to the GLUT4 promoter.
To understand the mechanisms involved in the transcrip-
tional inhibition ofGlut4, Mef2a and Pgc1α by ER stress, we
sought to evaluate the role of Atf6, a gene whose expression
has been reported to be upregulated during ER stress and may
cause inhibition of gene expression via upregulation of the
orphan nuclear receptor small heterodimer partner (SHP) in
pancreatic beta cells [30]. To test the hypothesis that the
overexpression of ATF6 is sufficient to impair GLUT4
expression, we generated L6 cell lines stably overexpressing
Atf6 (Fig. 5a). In Atf6-overexpressing cells, Glut4 mRNA
levels were reduced by 60% in basal condition (Fig. 5b), and
were further decreased by 75% upon GlcN treatment
(Fig. 5b). Atf6 overexpression also induced similar decreases
of Mef2a and Pgc1a expression compared with control cells
(data not shown). Treatment with a specific siRNA for Atf6
significantly inhibited the mRNA level of Atf6 in both
untreated and GlcN-treated cells (Fig. 5c). As expected, the
transfection of cells with an siRNA for a non-eukaryotic
gene, used as negative control, did not affect the upregulation
of Atf6 induced by GlcN (Fig. 5c). In addition, the siRNA for
Atf6 completely prevented GlcN-induced downregulation of
Glut4, Mef2a and Pgc1α (Fig. 5d). L6 cells were also
transfected with an siRNA for Shp (also known as Nr0b2).
As expected, the treatment with the siRNA for Shp
significantly inhibited the mRNA level of Shp in both
untreated and GlcN-treated cells (ESM Fig. 3a); by contrast,
it was not able to prevent the GlcN-induced downregulation
of Glut4, Mef2a and Pgc1α (ESM Fig. 3b). These data
indicate that the activation of Atf6 is responsible for the
impairment of Glut4 expression during GlcN-induced ER
stress through a mechanism independent of Shp activation.
Finally, to evaluate GlcN effects on human skeletal
muscle cells we used cultured human skeletal muscle cells
that display several features of mature skeletal muscle and
that have been previously used for studies of muscle
metabolism [20]. In differentiated human muscle cells,
GlcN induced a significant increase of both BIP/GRP78
and ATF6 mRNA levels (Fig. 6a, b), indicating that also the
human skeletal muscle cells were sensitive to GlcN-induced
ER stress. In addition, pretreatment with PBA completely
prevented the increase of both BIP/GRP78 and ATF6
mRNAs observed upon GlcN treatment (Fig. 6a, b),
confirming in human skeletal muscle cells the results
obtained in the rat cells. In human myotubes, GlcN
treatment reduced the expression of GLUT4 MEF2A and
PGC1α mRNAs (Fig. 6c–e), and completely inhibited the
uptake of 2-DG upon insulin stimulation compared with
control cells (Fig. 6f). Furthermore, human myotubes
treated with GlcN in the presence of PBA exhibited no
differences in the mRNA expression of both GLUT4 and its
upstream regulators MEF2A and PGC1α (Fig. 6c–e) and a
rescue of insulin-induced 2-DG uptake (Fig. 6f) compared
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Fig. 3 Effect of ER stress on 2-DG uptake and Glut4 expression in
L6 myotubes. a L6 cells were pretreated or not for 1 h with 10 mmol/
l PBA or 5 mmol/l TUDCA and then treated with 7.5 mmol/l GlcN for
24 h. 2-DG uptake was measured following 30 min of insulin
stimulation (mean ± SD; n=5). **p<0.01; ***p<0.001. b, c Glut4
mRNA was determined by real-time RT-PCR analysis of total RNA
isolated from myotubes, using Gapdh as internal standard. mRNA
levels in treated cells are relative expression units (REU) to those in
control (mean ± SD; n=5). ***p<0.001. b Time course of Glut4
mRNA in L6 cells treated with 7.5 mmol/l GlcN for the indicated
times. c Glut4 mRNA was detected in L6 cells pretreated or not with
10 mmol/l PBA for 1 h, and then treated with 7.5 mmol/l GlcN for
24 h. d L6 cells pretreated or not with 10 mmol/l PBA for 1 h, and
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with control cells. Thus, GlcN-induced ER stress impairs
insulin sensitivity also in human skeletal muscle, at least in
part by inhibiting GLUT4, MEF2A and PGC1α expression.
Discussion
Glucose toxicity may contribute to impaired insulin action
in diabetes [22]. A widely accepted hypothesis regarding
the mechanism responsible for glucose-induced insulin
resistance is that glucose toxicity is mediated by increased
flux of glucose into the HBP [17, 26, 27]. Other studies
have shown that GlcN, but not HG, causes impairment of
insulin-stimulated IRS-1 tyrosine phosphorylation and
phosphoinositide-3-kinase activation, and that defective
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Fig. 4 Effect of ER stress on Mef2a and Pgc1α mRNA expression
and GLUT4 promoter binding in L6 myotubes. a–d Mef2a and Pgc1α
mRNAs were determined by real-time RT-PCR analysis, using Gapdh
as internal standard. mRNA levels in treated cells are relative
expression units (REU) to those in control (mean ± SD; n=4). *p<
0.05; **p<0.01; ***p<0.001. a Time course of Mef2a mRNA in L6
cells treated with 7.5 mmol/l GlcN for the indicated times. b Mef2a
mRNAwas detected in L6 cells pretreated or not with 10 mmol/l PBA
for 1 h, and then treated with 7.5 mmol/l GlcN for 24 h. c Time course
of Pgc1α mRNA in L6 cells treated with 7.5 mmol/l GlcN for the
indicated times. d Pgc1α mRNAwas detected in L6 cells pretreated or
not with 10 mmol/l PBA for 1 h, and then treated with 7.5 mmol/
l GlcN for 24 h. e, f Soluble chromatin was prepared from L6 cells
vehicle treated or treated with 7.5 mmol/l GlcN for 24 h as described
in Methods and immunoprecipitated with MEF2A antibody (e) or re-
immunoprecipitated with PGC1α antibody (f). Immunoprecipitates
were then amplified by real-time RT-PCR analysis using specific
primers for the analysed regions (mean ± SD; n=3). ***p<0.001
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protein kinase B activation by insulin is associated with
glucose- but not GlcN-mediated insulin resistance in
adipocytes [31]. Nevertheless, studies in several model
systems, including overexpression of GFAT and infusion/
treatment with GlcN have confirmed that increased flux
through HBP can lead to impaired glucose metabolism [27,
32]. Thus it seems likely that a role for the HBP in the
development of the metabolic syndrome and insulin
resistance will prevail. According to this, it has been
reported that GlcN infusion in rats induces insulin
resistance to glucose uptake at the level of both the whole
body and skeletal muscle [33]. Furthermore, GlcN induces
insulin resistance in vitro in skeletal muscle [34] and
adipose cells [35], by reducing the insulin-induced glucose
uptake.
Many investigators have suggested the reversible O-
acetylglucosamine modification of proteins as one possible
mechanism by which increased HBP activity may cause
insulin resistance and diabetes complications. However, the
causal relationship between increased flux through HBP
and insulin resistance has not been clearly established.
Recently, it has been reported that elevated GlcN levels
could interfere with correct protein folding in the ER,
inducing ER stress and impairment of cellular function in
hepatic cells, monocytes and smooth muscle cells [36]. On
the other hand, it has been described that ER stress and
UPR activation may play an important role in the
pathogenesis of type 2 diabetes [37], affecting both beta
cell function/survival [11–13] and obesity-induced periph-
eral insulin sensitivity in liver and adipose tissue [15, 28].
However, little is known about the role of ER stress in the
development of insulin resistance in skeletal muscle tissue.
A very recent study hypothesised a molecular convergence
of activated HBP and ER stress pathways leading to insulin-
resistance in L6 cells [38]. However, the causal link between
the O-glycosylation pathway and the ER stress pathway in
determining insulin resistance remained elusive. Indeed, cells
silenced for O-linked N-acetylglucosamine transferase, the
enzyme responsible for the addition of UDP-N-acetylglucos-
amine to Ser/Thr residues of proteins, and treated with GlcN
or HG, showed improved insulin-stimulated glucose uptake
without any effect on ER chaperone regulation [38].
In the present work, we suggest that ER stress may
represent the molecular link between GlcN and insulin
resistance in skeletal muscle cells. We show that high GlcN
concentrations, as well as the ER stress inducer Thap, cause
ER stress and the activation of the UPR in L6 rat skeletal
muscle cells, as demonstrated by increased expression of the
chaperone Bip/grp78 and of the transcription factor Atf6, the
phosphorylation of eIF2α and the increase of both the ex-
pression and splicing of the transcription factor XBP-1.
Furthermore, ER stress and UPR activation are induced by
GlcN in a model of human skeletal muscle cells [20],
suggesting that both rat and human skeletal muscle cells are
sensitive to GlcN-induced ER stress. More interestingly, HG
also induces ER stress in both L6 cells and human myotubes
(data not shown). Pretreatment of cells with azaserine, a non-
specific but commonly used inhibitor of GFAT [26, 27]
prevented HG-induced ER stress, suggesting that at least in
part HG levels cause ER stress through hexosamines
production. In addition, others [34] and we have shown that
L6 myotubes are insulin-resistant upon GlcN as well as HG
treatment, as demonstrated by the significant decrease in their
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capability to take up the glucose analogue 2-DG upon insulin
stimulation. To gain further insight into the mechanisms
leading to insulin resistance, Bailey and Turner [34] evaluated
GlcN-induced insulin-resistance in L6 myotubes using three
different insulin-sensitive acting agents. None of these agents
was able to prevent GlcN-induced insulin resistance [34],
suggesting that GlcN does not impair insulin sensitivity by
altering the upstream steps of insulin signalling. It has been
shown that inhibition of insulin-stimulated glucose uptake by
GlcN is due to intracellular ATP depletion in rat skeletal
muscle [31], adipocytes [39] and chondrocytes [40]. Howev-
er, in other cell types, ATP depletion by exposure to sodium
azide or dinitrophenol did not mimic the effects of GlcN to
induce insulin resistance [41]. Thus, ATP depletion is not the
sole mechanism underlying all of the effects of GlcN. Indeed,
we show that GlcN does not induce ATP depletion at the
concentrations used in this study, suggesting that GlcN effects
on both ER stress and insulin-resistance were not dependent
on ATP depletion in skeletal muscle cells. Interestingly, we
have found that pretreatment of both rat and human myotubes
with PBA or TUDCA, two chemical chaperones known to
prevent ER stress and the UPR activation in different cellular
systems [15, 28], completely prevents the effect of GlcN and
HG on both ER stress induction and insulin-induced glucose
uptake, suggesting that GlcN-induced insulin-resistance is, at
least in part, dependent on ER stress.
Glucose uptake into skeletal muscle is primarily medi-
ated by GLUT4 [29]. Since it is well documented that
insulin resistance in type 2 diabetes can be associated with
a marked reduction in GLUT4 expression [42] and/or
translocation [43], we hypothesised that GlcN-induced ER
stress might affect transcription of the gene for GLUT4 in
both rat and human muscle cells. Here we show that this is
the case, as both GLUT4 gene mRNA and protein levels
are decreased by 50% upon GlcN as well as upon Thap and
HG treatment. Both the human and the rat GLUT4 gene
promoter are regulated through the cooperative function of
two distinct regulatory elements, domain 1 and MEF2
domain, each required for the maximal transcription of
GLUT4 promoter. Domain 1 binds the transcription factor
GEF (GLUT4 enhancer factor); MEF2 domain binds
transcription factor isoforms MEF2A and MEF2D [42].
MEF2A and GEF associate and function together to
activate GLUT4 gene transcription [44]. Little is known
about GEF, whilst the role of MEF2A as the main regulator
of GLUT4 gene is well documented. Indeed, MEF2A
reduced activity correlates with decreased Glut4 transcrip-
tion in skeletal muscle of diabetic mice and its activity is
completely normalised after insulin treatment [45]. GLUT4
gene transcription can also be modulated in skeletal muscle
by other proteins, such as PGC1α [46]. PGC1α is a
coactivator of MEF2A. Indeed, MEF2D binds PGC1α,
recruiting this transcriptional coactivator to MEF2A [42].
Moreover, PGC1α expression is reduced in skeletal muscle
of prediabetic and diabetic individuals [47], and enhanced
GLUT4 mRNA expression coincides with increased
PGC1α mRNA in human skeletal muscle cell culture after
treatment with rosiglitazone [46]. Our data, obtained in
both rat and human myotubes, show that both GlcN- and
HG-induced GLUT4 inhibition is paralleled by a significant
decrease of both MEF2A and PGC1α gene mRNA
expression, indicating that GlcN-induced GLUT4 inhibition
is exerted very likely at the transcriptional level. Further-
more, mRNA stability of those genes does not appear to be
affected by GlcN-dependent ER stress (data not shown).
These observations were confirmed by ChIP and re-ChIP
experiments, showing a reduced binding of both MEF2A
and PGC1α to Glut4 promoter. Again, these effects appear
to be mediated by ER stress signalling, since PBA or
TUDCA pretreatment of myotubes is able to prevent
GLUT4, MEF2A and PGC1α gene inhibition following
both GlcN and Thap treatments. These observations
prompted us to consider the GlcN-induced insulin resis-
tance of skeletal muscle cells as a consequence of GLUT4
inhibition and, therefore, reduced membrane translocation
(data not shown). However, the contribution of additional
components known to be relevant to insulin resistance
caused by ER stress in adipocytes and skeletal muscle cells
[15, 38], such as JUN N-terminal kinase activation, cannot
be excluded. Different proteins have been described to be
activated by ER stress and to play a role in ER stress-
mediated transcriptional repression. Very recently, indeed,
ER stress-dependent activation of ATF6 has been reported
to impair insulin gene expression in INS-1 pancreatic beta
cells cultured in HG conditions or treated with different ER
stressors, via upregulation of SHP [30]. We demonstrate
that the overexpression of Atf6 is sufficient to inhibit the
expression of Glut4, Mef2a and Pgc1α both in basal
conditions and upon GlcN treatment and that the silencing
of Atf6 expression with a specific siRNA is sufficient to
completely prevent GlcN-induced downregulation of Glut4,
Mef2a and Pgc1α. This effect seems to be independent of
the upregulation of SHP, since its silencing does not modify
Glut4, Mef2a and Pgc1α in skeletal muscle cells upon
GlcN treatment.
It has been recently shown that ATF6 is responsible for
cystic fibrosis transmembrane conductance regulator tran-
scriptional repression by binding to its promoter [48]. Our
analysis of the minimal promoter region of Glut4, Mef2a
and Pgc1α (GenBank accession numbers: NC_005109.2,
NW_001084766.1 and NC_005113.2), using MatInspector,
identified several putative binding sites for ATF6 and for
other UPR regulatory factors. Further studies will be
necessary to understand if ATF6 could repress Glut4,
Mef2a and Pgc1α expression in our cell models through a
similar mechanism.
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In conclusion, in this work we show that GlcN- as well as
HG-induced ER stress causes insulin resistance in both
human and rat myotubes and impairs GLUT4 gene expres-
sion and insulin-induced glucose uptake via an ATF6-
dependent decrease of the GLUT4 regulator genes for
MEF2A and PGC1α. Interestingly, treatment with the
molecular chaperones PBA and TUDCA completely pre-
vents HG- and GlcN-induced UPR activation and restores
insulin sensitivity in myotubes. These findings are particu-
larly relevant for understanding the molecular mechanisms
of glucose toxicity in skeletal muscle and of the conse-
quences of ER stress in the pathogenesis of type 2 diabetes.
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